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ABSTRACT
THE ROLES OF PANCREATIC BETA CELL ANTIOXIDANTS IN ISLET
TRANSPLANTATION AND TYPE 1 DIABETES
Xiaoyan Li
August 5, 2004

Pancreatic beta cells are extremely vulnerable to destruction by Reactive Oxygen Species
(ROS). In type 1 diabetes and islet transplantation ROS are thought to be involved in the
loss of beta cells. To test the role of antioxidant in islet transplantation. In our lab we
have determined that transgenic overexpression of the antioxidant protein metallothionein
(MT) in pancreatic beta cells provides broad resistance to oxidative stress by scavenging
most kinds of ROS. A direct test of hypoxia/reperfusion sensitivity was shown that MT
markedly reduced ROS production and improved islet cell survival. Furthermore, in both
syngeneic transplantation and allotransplantation, MT islets preserved high insulin
content and extended the duration of euglycemia two-fold longer than nontransgenic
islets. The time course of protection suggested that the major mode of MT action may
have been protection from hypoxia or hypoxia/reperfusion.

To test the role of antioxidants in type 1 diabetes, three lines of antioxidant transgenic
NOD mice were produced with

~-cell

specific overexpression of MT, catalase (Cat) or

MnSOD. Unexpectedly, the two cytosolic antioxidants, MT and Cat, but not

IV

mitochondrial MnSOD, dramatically hastened both spontaneous onset diabetes and
cyclophosphamide (CYP) induced diabetes in NOD mice. MT and Cat transgenic ~-cells
died by apoptosis more rapidly than control
ROS may have some protective role in
has

been

recognized

~-cells.

~-cells

These data indicate that cytoplasmic

against type 1 diabetes, which is a role that
some

In

other

cell

types.

To elucidate this protective mechanism, we assessed the status of the PI3KJAkt/FoxolIPDX-1 pathway, one of the most important survival pathways in the

~-cells.

Western

blots of islets from transgenic and control NOD mice showed that both in vivo after CYP
injection and in vitro after cytokine treatment phosphorylation of Akt and Foxo-l, and
PDX -1 expression were significantly reduced in transgenic islets. In vitro MT sensitized
NOD islets to cytokine induced cell death even though MT efficiently scavenged
cytokine induced ROS production. Orthovanadate, a protein tyrosine phosphatase (PTP)
inhibitor rescued the sensitizing effect of MT to cytokine toxicity. Our data imply that
elevated cytosolic antioxidants may result in higher PTP activity in
PTPs from ROS, thereby cause decreased

~-cell

~-cells

by protecting

survival and accelerating type 1 diabetes

in NOD mice.

The data from this project demonstrated that overexpression of antioxidants protects
islets from ROS damage produced during early phase islet transplantation but sensitizes
~-cells

to diabetes in NOD mice.
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CHAPTER I
THE ROLE OF MT IN ISLET TRANSPLANTATION
INTRODUCTION
Diabetes mellitus

~iabetes

mellitus has been defined on the basis of disturbed carbohydrate metabolism,

specifically, hyperglycaemia. There are two major forms: Type 1 (insulin-dependent)
diabetes mellitus (100M) and Type 2 (non-insulin-dependent) diabetes mellitus
(NIOOM). In the United States, there are 18.3 million people, or 6.3% of the population,
who have diabetes. It is estimated that 5-10% of Americans who are diagnosed with
diabetes have type 1 diabetes. Approximately 90-95% (17 million) of Americans who
are diagnosed with diabetes have type 2 diabetes. In NIOOM, insulin resistant and beta
cell dysfunction have been identified as two major defects. However, 100M develops
as a consequence of the selective destruction of insulin-producing beta cells by an
autoimmune aggression.
In spite of extensive investigation, the etiology of both Type 1 and Type 2 diabetes is
still unknown, although genetic and environmental factors are found to be involved. The
evidence for genetic component of diabetes mellitus has come from family studies
including monozygotic investigation. Monzygotic twin concordance rates in NIOOM
may reach more than 90%, while in IDDM they do not exceed 50%.(1). Environmental
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factors including diet, exercise and age play very important role in the pathogenesis of
NIDDM. Also environmental factors such as hormonal, dietary, viral, climatic, toxic
and psychological events are shown to be involved in type I diabetes onset. (2-5).

Islet transplantation

Transplantation of pancreatic islets is considered to be one of the most effective
treatments for Type 1 diabetes (6). Recently, islet transplantation using the Edmonton
protocol (7) achieved insulin independence in 12 out of 15 diabetic patients for one year.
However wide spread application of transplantation therapy is still limited by the need
for more than one donor pancreas per recipient and difficulties in maintaining long-term
euglycemia (8). One obstacle has been that many islets are lost during the initial stages
of transplantation (9; I 0). Shortly after implantation islet grafts function poorly and
many transplanted beta cells undergo apoptosis prior to stable engraftment. This
increases the mass of islets needed to achieve euglycemia (11). Unfortunately there is
an extreme shortage of human pancreatic islet donors. Therefore instead of increasing
the number of islets implanted, a more desirable strategy is to improve islet graft
survival during the early stages of transplantation. However, to date no impressive
regimen has been devised to prevent early graft damage.

Reactive oxygen species (ROS) are involved in both early islet graft loss and longer
term immune rejection. Shortly after implantation, islet grafts are exposed to
nonspecific inflammatory events (12) that generate proinflammatory cytokines, nitric
oxide and reactive oxygen species (ROS). These local, nonspecific inflammatory
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mediators attack implanted islets. In the rat islet transplant model, grafts are destroyed
by high level of nitric oxide released from allogenic (13) or syngenic (14) macrophage.
In addition, the graft suffers from an initial period of hypoxic ischemia after
transplantation. Oxygen tension measured within the islet graft is initially very low (15).
In fact newly transplanted islets are essentially avascular, leaving them with insufficient
oxygen and nutrients until the process of revascularization is completed. This ischemic
microenvironment, followed by reperfusion as a consequence of revascularization,
produces conditions known to induce detrimental ROS in transplanted organs (16-18).

The damaging effects of ROS on pancreatic islets have been widely investigated in
diabetes (19;20) as well as in islet transplantation (21-23). Exposure of isolated human
islets (24), rodent islets (25 ;26) or beta cell lines (27) to ROS markedly inhibits beta cell
function and results in beta cell death. Compared to other cell types, pancreatic beta
cells are particularly susceptible to destruction caused by ROS (28). This is probably
because islet cells contain very low levels and activities of several ROS detoxifying
systems (29). Recent studies reported that early islet graft loss could be ameliorated by
various antioxidant combinations such as a-tocopherol (30) and other vitamins (31).
Other reports have investigated transgenic overexpression of single, specific antioxidant
protein.

Protection from mitochondrial superoxide radical by adenoviral mediated

expreSSIOn of MnSOD (32) was sufficient to extend islet graft function by 50%.
However, in our laboratory, we found that overexpression of the specific, hydrogen
peroxide detoxifying protein catalase failed to prevent insulin loss in syngeneic islet
grafts (33). To test whether beta cell protection could be improved by protecting against
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multiple species of ROS several laboratories have expressed more than one antioxidant
enzyme. In insulin secreting RINm5F cells, combined expression of Cu/Zn SOD plus
catalase or Cu/Zn SOD plus glutathione peroxidase provided more protection against
hydrogen peroxide, superoxide radical, and nitric oxide than expression of either
transgene alone (34;35). Co-administration of SOD and catalase in cultured rat islets
more effectively prevented alloxan induced destruction than either antioxidant alone
(36). These results indicated that enhanced protection was possible by scavenging more
than one species of ROS. Therefore, we hypothesized that a significant improvement of
islet graft survival could be achieved if the donor islets were protected by a potent
antioxidant protein with a broad

spectrum of ROS scavenging activity, such as

metallothionein (MT).

MT is a low molecular weight, cysteine-rich and highly inducible protein that binds
heavy metal with high affinity. MT appears to play an important role in metal
metabolism and detoxification. Due to its many cysteine residues MT also functions as
a potent antioxidant. Elevated expression of MT in pancreatic beta cells, produced
either by zinc induction (37;38) or by transgenic techniques (39), has been shown to
protect from streptozotocin (STZ) induced beta cell damage and diabetes.

Studies in

cell-free system have demonstrated that MT is able to scavenge a wide range of ROS
including superoxide, hydrogen peroxide, hydroxyl radical and nitric oxide at higher
efficiency than other antioxidants such as GSH (40-42). However, it is not certain that
MT will provide such a broad spectrum of antioxidant function in vivo.
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MATERIALS and METHODS
Animals
MT transgenic mice were established in our laboratory on the FVB strain with
pancreatic beta cell overexpression of the human MT II gene, as described previously
(43). In more detail, the MT transgene, designated HMT, was constructed utilizing the
plasmid INS.HBS provided by Dr. Timothy Stewart (Genentech, California).

This

plasmid contained the human insulin promoter and first intron followed by unique
BamH I and Hind III sites. A 2.4 kb Nco I I Hind III fragment containing all introns
and exons of the human MT II gene was ligated behind the insulin promoter utilizing
the BamH I and Hind III sites of INS.HBS. Prior to ligation the Nco I and BamH I sites
were blunt ended with Klenow polymerase. Before microinjection, the 4100 bp HMT
trans gene was removed from plasmid sequences by cutting with Hind III and EcoRI.
The HMT - I transgenic line was used in this study since this line has the highest
expression of MT. Recipient Balb/c mice were purchased from Jackson Laboratory (Bar
Harbor, Maine). All mice were housed in ventilated cages at the University of
Louisville Research Resources Center with free access to water and standard mouse diet.
All animal procedures were approved by the Institutional Animal Care and Use
Committee, which is certified by the American Association of Accreditation of
Laboratory Animal Care.

Chemicals
Streptozotocin, 3-morpholinosydnonimine (SIN -1), S-nitro-N -acetyl-penicillamine
(SNAP), hypoxanthine, xanthine oxidase, collagenase (type V), Ficoll and trypsin were
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obtained from Sigma (St. Louis, MO). Hank's balanced salt solution (HBSS), RPMI
1640 medium, and fetal bovine serum (FBS) were supplied by Gibco BRL (Rockville,
MD). Rat insulin standard was bought from Linco (St. Charles, MO). Rabbit antiserum
to guinea pig insulin, was purchased from BioGenex (San Ramon, CA). Monoclonal
anti-nitrotyrosine antibody was supplied by Cayman (Ann Arbor, MI).
chloromethyl-2',

7' -dichlorodihydrofluorescein

diacetate

(CM-H2DCFDA)

5-(6)was

purchased from Molecular Probes (Eugene, OR). Alamar Blue was purchased from
Biosource International (Camarillo, CA).

Islet preparation

The isolation procedure was based on a modification of the method of Gotoh et al (44)
and has been described previously(45). Isolated islets were cultured overnight in RPMI1640 medium containing

10% BSA, 2% Penicillin-Streptomycin before the

transplantation and in vitro studies, which were performed on the second day.

Measurements of ROS production

To measure ROS production in single islet cells, the overnight cultured islets were
first dispersed into individual cells by treatment with trypsin (0.0075%) in Ca2+ and
Mg2+ free Hanks' solution at 37°C for 10 min followed with mechanical dispersal by
50 times of repeat pipetting, as described previously (46). A cell membrane-permeable
and

oxidant

sensitive

fluorescent

dye

5-(6)-chloromethyl-2',

7'-

dichlorodihydrofluorescein diacetate (CM-H2DCFDA) was used to measure ROS. The
dispersed islet cells were loaded with 10 IlM CM-H2DCFDA for 30 min followed by

7

three washes of fresh culture medium without phenol red. The cells were resuspended in
culture medium without phenol red. After the cells were counted, the dispersed islet
cells containing CM-H2DCFDA were distributed into a 96-well plate at concentration of
40,000 cells per well in 200 /-ll islet culture medium without phenol red. The exogenous
sources of ROS: H20 2, SIN-lor hypoxanthine/xanthine oxidase, were added quickly to
the wells. With the addition of ROS, the increase of fluorescence intensity in each well
was measured on a fluorescent microplate reader (Tecan, Durham, NC) at an excitation
wavelength of 485 nm and an emission wavelength of 530 nm. The data were expressed
as fluorescent intensity per 40,000 cells.
ROS production in whole islets following hypoxia treatment was measured with a
method modified from the procedure of Ye, et al (47) in our laboratory. Briefly, the
hypoxia treated or untreated FVB control or MT transgenic islets were loaded with 5
/-lM CM-H2DCFDA for 30 min followed by three washes of fresh culture medium. The
fluorescence of each islet was activated at an excitation wavelength of 485 nm and
recorded at an emission wavelength of 530 nm. ROS was monitored from randomly
sampled individual islets using an Olympus IX70 inverted microscope equipped with a
digital cooled CCD camera. Images were analysed with ImagePro software (Media
Cybernetics, Silver Spring, MD). More than one hundred islets from at least three
separate islet isolations were studied for each group. The results were expressed as the
mean fluorescence intensity.

Nitric oxide in vitro studies
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Isolated FVB and HMT-1 islets were exposed to different concentrations of a nitric
oxide donor, S-nitro-N-acetyl-penicillamine (SNAP) for 24 hrs. Apoptotic and necrotic
DNA were detected with an anti-histone biotin/anti-DNA POD ELISA

p1us

kit (Roche,

Indianapolis, IN) based on the manufacturer's instructions. Briefly, 40 to 50 islets were
cultured for 24 hrs in 500 III fresh culture medium in a 1.5ml microtube with or without
SNAP treatment. After treatment the microtube was centrifuged at 200x g for 10 min at
4°C. The supernatant was removed as the necrosis DNA sample. The pellet was lysed
with 100 III lysis buffer for 30 min at room temperature. The microtube was centrifuged
again at 200x g for 10 minutes at 4°C. The supernatant was removed as apoptotic DNA
sample. To quantify the necrotic and apoptotic DNA, both DNA samples were added to
the streptavidin-coated microplate contained in the kit. All values were normalized to
islet total DNA measured by picogreen DNA quantification (Molecular Probes, Eugene,
OR).

In vitro hypoxia treatment
Isolated FVB and HMT -1 islets were cultured in a 96-well plate placed in a sealed
incubator chamber saturated with 1% 02' 5% CO2 and 94% N2 at 37°C. After
incubation for 24, 48, or 72 hrs, the islet cell viability was assessed by measuring islet
metabolism as indicated by alamar blue absorbance. The data for cell viability were
calculated as the percentages of viability of control cells that were cultured normally in
95% air, 5% CO 2, ROS production in islets after hypoxia for 7 hrs was measured with
CM-H2DCFDA fluorescence dye, as described above.
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Alamar Blue assay
The Alamar Blue assay, which incorporates a redox indicator that changes color and
fluorescence in response to cell metabolic activity, is a commonly used method to
assess cell viability and/or proliferation of mammalian cells (48) and micro-organisms
(49). In our studies, 15 overnight-cultured FVB control islets or HMT -1 transgenic
islets were hand picked into 200 ul fresh culture medium (no phenol red) containing
1:20 diluted Alamar Blue in a 96-well plate. Islets were cultured for 4 hr and the
Alamar Blue fluorescence was measured on a fluorescent microplate reader (Tecan,
Durham, NC) at the excitation wavelength of 535 nm and the emission wavelength of
595 nm. This measurement provided an absorbance value indicating the pretreatment
metabolic activity and was used to normalize the post-treatment metabolic activity.
After three washes with fresh culture medium, islets were cultured in 200 ).11 culture
medium under normoxia or hypoxia (1 % 02) conditions for varying time periods. At the
end of treatment, 50 III culture medium was replaced with 50 III fresh culture medium
containing 1:5 diluted Alamar Blue, for a final dilution of 1:20. The color was
developed for another 4 hr and the fluorescence was measured again. Islet cell viability
was calculated as the ratio of fluorescence after treatment to the fluorescence before
treatment.

Syngeneic transplantation
50 FVB and HMT -1 islets were transplanted separately under each kidney capsule in
a normal FVB mouse according to a modification of the procedure of Montana et al
(50). Recipient mice were anesthetized via ip. injection with lOlli/gram of a solution
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containing 10 mg/ml ketamine and 3.2 mg/ml xylazine. The left side kidney was first
externalized through a small incision and kept moist with saline. 50 islets were picked
into a gel-loading pipette tip (0.5 mm diameter) mounted on a l-cc Hamilton syringe
(Reno, NV) and allowed to settle. The tip was inserted through an incision beneath the
kidney capsule and the islets were gently forced out of the tip. The body wall and the
skin were closed with sutures. Then the transplantation to the right kidney was
performed by the same procedure. Six days later, grafts were recovered by removing a
portion of the kidney far exceeding the visualized graft site. This portion of the kidney
was homogenized in acid ethanol (23 ethanol: 2 HC1: 75 H20, v/v/v) for insulin
extraction. To determine the insulin content we used an anti-insulin antibody coated
tube RIA kit (Diagnostic Products, Los Angeles, CA) and rat insulin standards
according to the manufacturer's instructions. Briefly, 400 III of diluted sample or rat
insulin standard solution was mixed thoroughly with 1 ml of 125 Iodine labeled insulin in
the anti-insulin coated tubes. After overnight incubation at room temperature, tubes
were washed three times and the radioactivity for each tube was counted in a gamma
counter. The sample insulin values were within the 20% to 80% bound capacity of the
radioimmunoassay. Insulin content was calculated from a standard curve made with rat
insulin standards.

Allotransplantation

200 FVB or HMT -1 islets were transplanted under each kidney capsules (400 total)
with the same protocol described above.

Before transplantation, the recipient Balb/c

mice, aged 8-12 weeks, were injected with a single dose of STZ (ip. 220mg/kg) to
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induce diabetes. Only mice with blood glucose ranging from 350 mg/dl to 500 mg/dl
were used as recipients for transplantation surgery. After transplantation the mice were
allowed to recover freely without treatment. Tail blood glucose levels of the
transplanted mice were monitored every other day with a glucose meter (OneTouch
Ultra, Life Scan, Milpitas, CA). Graft failure was defined as a return of hyperglycemia
(nonfasting blood glucose> 250 mg/dl) on two consecutive measurements. Islet graft
survival time was calculated as the number of days from transplantation to the first day
of hyperglycemia of two consecutive measurements. Grafts from some recipients were
recovered 6 days after transplantation and sectioned for hematoxylin/eosin and
nitrotyrosine staining.

In separate experiments in which only one kidney was

transplanted we verified that removal of the graft containing kidney caused a return to
glucose levels over 600 mg/dl.

Immunohistochemistry for nitrotyrosine

Islet grafts were fixed in 10% formaldehyde in 0.1 mollL phosphate buffer (pH 7.2),
dehydrated in an ascending graded series of ethanol, and subsequently infiltrated with
paraffin. Serial section were cut at 5 11m, mounted on polylysine-coated slides, and then
deparaffinized in xylenes and a descending graded series of ethanol. For nitrotyrosine
staining, slides were treated with target retrieval solution (Dako corporation, Carpinteria,
CA), followed by M.O.M mouse Ig blocking reagent (Vector Laboratories, Burlingame,
CA). Nitrotyrosine monoclonal antibody (Cayman, Ann Arbor, Michigan) was added
the slides at a concentration of 10 Ilg/ml and incubated overnight at 4°C. After 3 washes
in phosphate-buffered saline, slides were incubated with biotinylated anti-mouse IgG
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reagent, followed by ABC reagent and developed with DAB as chromagen. Slides
without primary antibody treatment were used as negative control. For quantification of
nitrotyrosine production, 5 MT graft slides and 5 FVB control graft slides from three
independent recipients were scored on a scale from I to 5 grades based on the severity
of nitrotyrosine staining by two researchers blind to the identity of the section.

Data analysis

Data are presented as the mean ± standard error. Statistical significance was
performed by one-way or two-way ANOVA and Dunnet's post hoc (2-tailed) test.
Kaplan-Meier survival analysis and Mantel-Cox Log-rank test were used to analyze
islet graft survival time. Mann-Whitney Rank Sum Test was used to analyze
nitrotyrosine staining in islet grafts. Computations were done using statistical programs
from SPSS (version 10.0) and Sigmastat (version 2.03).
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RESULTS

Broad spectrum ROS scavenging by MT: Our previous study (51) demonstrated that
the MT transgene protected against ROS released by STZ. To determine if MT could
protect against many species of ROS, beta cells were exposed to H20 2, superoxide
radical produced by hypoxanthine and xanthine oxidase, and peroxynitrite radical
released from SIN-I. Beta cell ROS production measured with CM-H2DCFDA (Figure
1-1) was dramatically reduced by the MT trans gene following exposure to all three
sources. Islets were also exposed to nitric oxide by incubation with SNAP, a nitric oxide
donor. SNAP did not increase CM-H2DCFDA fluorescence in our assay; consequently
we assessed MT induced resistance to nitric oxide by observing changes in islet
morphology and quantitating islet cell death. As shown in Figure 1-2, MT islets were
resistant to SNAP induced morphological damage and cell death as measured by DNA
cleavage. These data demonstrate that MT is able to efficiently scavenge all or most
forms of free radicals.

In vitro hypoxia studies:

Hypoxia and reoxygenation are known to induce ROS

production (52;53). To determine if MT could reduce hypoxia induced ROS production
we exposed isolated FVB control and MT transgenic islets to 1% O 2. This is close to
the microenvironment that transplanted islets are subject to at the graft site (54). ROS
production was measured with CM-H2DCFDA following 7 hrs of hypoxia and return to
normoxic media. The data in Figure 1-3 illustrate the effect of the hypoxia incubation
on ROS generation. Both FVB and MT islets produced more ROS following exposure
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to hypoxia. However the ROS generation was significantly greater in FVB islets than
in MT islets. To determine if this reduction in ROS generation translated into improved
islet survival, we assessed islet viability with the metabolism sensitive dye Alamar Blue.
MT and FVB islets were exposed to 1% O 2 for 24, 48, and 72 hrs and then assayed with
Alamar Blue. As shown in Figure 1-4, islet cell metabolism was markedly decreased by
hypoxia treatment. Overexpression of MT provided significant resistance to this effect
at all time points analyzed.

Transplantation: Hypoxia and/or hypoxia reoxygenation are toxic stressors that
grafted islets must contend with during the early phase of transplantion while
revascularization progresses. To determine if the ability of MT to protect against
hypoxia and reoxygenation would be beneficial in a real transplantation situation, islets
were transplanted into syngeneic, nondiabetic FVB recipients. These grafts are subject
to hypoxia but not to immune rejection or glucose toxicity. MT transgenic islets were
implanted under one kidney capsule and control FVB islets were implanted under the
other kidney capsule of the same recipient. Six days after transplantation the graft was
recovered for determination of insulin content.

Insulin content is a commonly used

indicator of transplanted islet health (55;56). Figure 1-5 illustrates that both FVB and
MT islet grafts lost part of their insulin content after transplantation. However, FVB
islets were more severely affected. MT islets retained about 60% of their initial insulin
content, whereas FVB islets retained less than 20% of their initial insulin (p<O.OI).
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We also carried out allotransplantation studies usmg FVB control islets or MT
transgenic islets implanted under the renal capsules of STZ induced diabetic Balb/c
mice (Figure 1-6). 400 FVB islets were able to maintain near normal blood glucose
levels in recipient mice for an average period of 8.36 ± 1.67 days. The same number of
MT transgenic islet was more effective.

Average euglycemic period for recipients

receiving MT islets was almost doubled, to 16.2 ± 2.52 days. Mantel-Cox Log-rank
analysis of islet graft survival time indicated that MT grafts were significantly (p<O.OI)
more effective in maintaining euglycemia.

To confirm that the prolonged survival of MT islets was due to protection from ROS
nitrotyrosine staining in islet grafts recovered after 6 days of transplantation was
measured. Nitrotyrosine is a marker for the presence of peroxynitrite. As shown in
Figure 1-7, nitrotyrosine staining in MT grafts was markedly decreased compared to
nitrotyrosine staining in control FVB islet grafts. This result was confirmed by blind
ranking of nitrotyrosine intensity on 5 MT and 5 FVB graft slides from three different
recipients per group (p<0.02).
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DISCUSSION

In the present study we demonstrated that overexpression of MT reduced ROS levels in
beta cells exposed to many different prooxidant stimuli. Protection from ROS helped
preserve islet viability after treatment with an NO donor or prolonged exposure to
hypoxia. MT transgenic islets maintained almost three fold higher insulin content than
control islets following syngeneic transplantation.

Transplantation with MT islets

prolonged euglycemia by two fold compared to transplantation with control islets and
MT reduced the formation of nitrotyrosine in islet grafts into allogeneic, diabetic
recipients. The greatest benefit of MT was probably due to protection from hypoxia
rather than due to prevention of immune rejection.

Islets are exposed to many noxIOUS ROS during transplantation and the onset of
diabetes. These different ROS can produce additive or synergistic toxicity to beta cells
(57;58). Therefore it is important that antioxidant treatment protect against as many
different types of ROS as possible. However, most enzymatic antioxidant proteins are
specific in their substrate and thus limited in the types of ROS that they can inactivate.
Catalase and glutathione peroxidase decompose primarily hydrogen peroxide, and SOD
activity is specific to superoxide. An example of the restricted protection provided by a
single antioxidant enzyme is the recent demonstration (59) that elevated MnSOD
expression protected islets from alloxan but provided no protection from nitric oxide.
Unlike enzymatic antioxidants, MT has broad antioxidant activity. In cell-free system
MT has been shown to scavenge nitric oxide radical (60) superoxide radical (61),
hydroxyl radical (62) and peroxynitrite (63). We confirmed that MT was effective
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against all of these ROS when expressed in transgenic pancreatic islets and also showed
that MT reduced apoptosis and necrosis produced by nitric oxide exposure. Nitric oxide
is generally considered to be an important mediator of beta cell damage produced by
many stressors (64).

The efficacy of MT against most ROS means that MT

overexpression can provide a general test of the role of ROS in beta cell damage
produced during transplantation and diabetes.

MT overexpression was able to extend the duration of euglycemia by two fold in
allogenic recipient diabetic mice.

This amounted to an increase of 8 days.

The

relatively short period of improved graft function suggests that MT protects most
effectively against the damage produced in the early phase of transplantation, prior to
immune rejection of the graft. Consistent with this we found that MT protected graft
insulin content in syngeneic recipients, which is in the complete absence of immune
rejection. Although there are many factors that contribute to early graft loss, evidence
suggests that hypoxia is one important factor. Islet grafts are initially an essentially
avascular tissue. Mean P02 measured in syngeneic transplanted islets (65) is 5-10
mmHg (about 1% 02). Low levels of oxygen can impair islet cell function and cell
survival. It has been shown that there is a strong correlation between reduced oxygen
supply and the occurrence of apoptosis in isolated human and rat islets (66). Islet grafts
are particularly prone to destruction caused by hypoxia followed by reoxygenation
during the process of revascularization (67). The loss of cell viability produced by in
vitro hypoxia in the present study is consistent with this sensitivity. MT was very

effective in blocking ROS generation and cell death produced by hypoxia. Because our
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fluorescence detection system was not sealed from air the generation of ROS may have
been due to hypoxia or hypoxia/reperfusion.

Several studies have used systemic antioxidants to extend efficacy of islet transplants
(68-71) with varying degrees of success. To improve outcome and focus protection on
the islet, Bertrea et al (72) transplanted islets with adenoviral mediated overexpression
of MnSOD into an NODscid model of immune rejection.

This produced a 50%

extension of graft function, possibly due to protection from immune attack. We found
that MT produced a similar or modestly greater degree of protection. Since experiments
were performed in different models direct comparison are impossible. Clearly neither
transgene provided complete protection.

MT is cytoplasmic and protected against

hypoxia, while MnSOD is mitochondrial and was thought to protect against immune
attack. Potentially combination of these two differentially localized antioxidants with
different modes of action may produce additive or synergistic benefit.

Successful clinic trials using the Edmonton protocol provide encouraging results for
islet transplantation. However, the need for multiple donors hampers successful and
efficient clinical islet transplantation. The shortage of organ donors is an intractable
problem. Therefore any significant improvement in graft efficiency is worthwhile. MT
improved islet function by reducing damage secondary to hypoxia. This demonstrates
that powerful ROS scavengers are beneficial for transplanted islet survival and may be
useful in combination with other strategies aimed at islet graft protection.

19

A

400 -

~

'iii
c

C

c

41

f

u:g

300

C

200

C

C

~

1

~

'iii

300

S

B

400

200

41

100

C.)

UI

i!!
o

°M~~n

100

::s

o

-100

o

100

200

300

400

500

o

100

~
UI

-C

41

C

C

41

C.)

UI

i!!
o

::s

u.

300

400

500

400

500

Time (minutes)

Time (minutes)

C

600

200

~

500

'iii
c

.s

400

-,=

300

C

41

200

C.)

~

100

o

::s

o

u::

-100

o

100

200

300

400

500

Time (minutes)

o

100

200

300

Time (minutes)

Figure 1-1. ROS production in dispersed FVB control and transgenic MT islet cells,
ROS was measured with the fluorescent dye CM-H2DCFDA as described in Methods.
Islet cells were not treated (A), treated with 100 IlM H20 2 (B), treated with 30 IlM SIN1 (C), treated with 1 mM hypoxanthine plus 2 mU xanthine oxidase (D). The solid
circles indicate FVB control islet cells. The open circles indicate MT transgenic islet
cells. This figure is typical of three independent experiments.
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Figure 1-7. Nitrotyrosine production in FVB and MT allografts 6 days after
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MT transgene significantly reduces nitrotyrosine production in islet grafts (P<O.02 by
Mann-Whitney Rank Sum Test). The horizontal lines indicate the mean score.
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CHAPTER II
THE ROLE OF ANTIOXIDANTS IN TYPE 1 DIABETES
INTRODUCTION
Autoimmune nature of IDDM

IDDM is aT-cell mediated autoimmune disease in which the insulin-producing beta
cells of the pancreatic islets are destroyed. The involvement of defective regulation of
the immune function supports the view that type 1 diabetes is an autoimmune disease .
The key evidence for the autoimmune nature of type 1 diabetes includes the importance
of the major histocompatibility complex (MHC) genetic background, the presence of
mononuclear cells infiltrating pancreatic islet (insulitis), autoantibodies to various islet
antigens (including beta cell specific and non-specific antigens), abnormal cellular
immunity, and beneficial effect of immunosuppressive therapy.

In humans, genetic susceptibility to IDDM is mainly associated with two chromosomal
gene regions: the IDDMI locus containing the genes for MHC (IDDI in NOD mouse),
which contributes to 42% of familial inheritance of the disease, and the IDDM2 locus,
which accounts for 10% of inheritance(73). Both in the NOD mouse and in humans,
specific MHC genes are necessary but not sufficient for diabetes development(74).
MHC genes are thought to control autoimmune susceptibility through class I and II
molecules in the selection of the peripheral T-cell repertoire within the thymus and
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through the restricted presentation of autoantigen-derived peptides to T lymphocytes
(75).

In both human and animal models, the onset of type 1 diabetes is preceded by a long
phase of clinically latent islet-ceIl-specific infiltration by lymphocytes, called insulitis.
A key finding in IDDM patients that die early in the course of their disease is insulitis.
Studies in spontaneous model of NOD mouse have shown that around 3 weeks of age,
swollen vessels resembling high endothelial venules are first seen adjacent to islets,
followed by an increase in the number of dendritic-like cells and macrophages, APC
within the vessel wall and at the side of the islet near the vessel. From 4 to 6 weeks of
age, periinsulitis occurs, which is composed of an accumulation of APC, B and T
lymphocytes around the outside of the islets (76). Insulitis increases with age and there
is a change in distribution with increasing intra-islet insulitis compared with periinsulitis .

However, in spite of extensive and active insulitis, intact beta cells persist for long
periods of time and no diabetes occurs. Eventually, this balance is lost and insulitis
becomes terminally aggressive. It has been shown that all NOD mice develop insulitis;
however, in many cases this inflammation is "benign" in that it does not result in the
destruction of the insulin-producing beta cells, causing hyperglycemia (77-79). Only in
a proportion of mice does the inflammatory process become "malignant" and result in
death of the beta cells and consequent hyperglycemia. The data suggested that
development of disease is correlated with a switch from a benign to malignant state of

29

autoimmunity. However, the mechanisms which precipitate this change from benign to
malignant inflammation are not well understood.

IDDM is also characterized by the presence of a variety of antibodies. Several IDDMrelated candidate autoantigens have already been identified in humans and lor animal
models, such as glutamic acid decarboxylase (GAD 65 and 67), insulin, proinsulin,
ICA 512/1A-2 and IA-2b/phogrin ( two different tyrosine phosphatase antibodies), 38
kDa antibodies such as imogen 38 and glima 38, peripherin, heat-shock protein (hsp) 60,
ICA 69 carboxypetidase H, and bovine serum albumin (80-88). Although it has never
been demonstrated that autoantibodies playa pathogenic role, their predictive values
make them invaluable markers for identification of preclinical diabetes (88-92). Some
autoantibodies are stongly associated with rapid progression to overt diabetes. For
example: Cytoplasmic islet cell antibody (lCA) was the first autoantibody described.
ICA are detected in 60-90% of patients with newly diagnosed IDDM and in 1 to 9% of
non-diabetic first degree relatives (88). Islet cell surface antibodies (lCSA) are present
in almost all recent-onset IDDM patients (93). Beta cell specific antibodies insulin (lAA)
and pro insulin autoantibodies (PAA) are also present in 16 to 69% of new diagnosed
IDDM patients and in 2 to 4% of first-degree relatives (88). Anti-GAD and anti-IA-2,
which are not specific to beta cells but are also expressed in neurons and various
endocrine cells (94), are also shown to be highly relevant to overt diabetes (88).
Several other antibodies have been described in IDDM such as anti-carboxypeptidase H
and antibodies to BSA, which appear to be less relevant for the prediction of the disease
either because of their low frequency or because of their lack of diabetes specificity (88).
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However, as stated above, the presence of autoantibodies in patient sera is not evidence
of their pathogenic potential(95). Autoantibodies may be a result of cellular destruction,
such as that of cardiac muscle cells after myocardial infarction which give rise to antiheart cell antibodies (96).

In both animal model and human patient, immunosuppressive drugs can benefit the
disease. T-cell-targeting agents such as anti-CD4, CD8, CD3 or cyclosporine and
induction of immune tolerance or islet auto antigens can prevent type I diabetes in
animal models. Treatment with immunosuppressive drugs e.g. azathioprine, steroids,
cyclosporine increases the remission rate in newly-diagnosed patients (97).

Type 1 diabetes animal model-----NOD mice

Although the number of type 1 diabetes patients has been projected to increase in the
next ten years, analysis of the pathogenesis of diabetes in humans has been limited to
the study of autopsy specimens from diabetic patients, or of in vitro effects using
isolated islets. Also the symptoms of diabetes appear late, once patients are diagnosed
as type 1 diabetes patients, most beta cells have been destroyed. Therefore it is difficult
to study the early phases of the disease in humans. Our understanding of the
pathophysiological events that precede diabetes development has benefited largely from
the accessibility of relevant models of IDDM in the mouse. Animal models for type 1
diabetes fall into two main groups. In the first group, IDDM is induced following an
external intervention such as the low-dose multiple streptozotocin model or virus-
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induced diabetes. The second group consists of two rodent models that spontaneously
develop type 1 diabetes, the NOD (non-obese diabetic) mouse and the BB (BioBreeding)
rat. These have been the most extensively studied animal models over the past 10 years.
Both models show striking similarities with human IDDM such as insulitis and
antoantibodies. The NOD mouse has proven to be the most informative and has
contributed substantially to clarifying the pathogenesis of autoimmune diabetes. Since
the NOD mouse has a better-defined genome, costs less, and also has more monoclonal
reagents available for the analysis of immune system components, the NOD mouse has
been regarded as the favored model for investigations into the pathogenesis of human
type 1 diabetes, ever since it was reported in Japan 20 years ago. In this strain, both
female and male NOD mice develop diabetes spontaneously, but the females are more
susceptible. In the female mice the incidence of diabetes is 90-100% by 30 weeks of age.
Male mice develop diabetes at a frequency of 40 to 60% by 30-40 weeks of age (98).
Similar to human type 1 diabetes patients, before becoming overtly diabetic, with nonfasting plasma glucose higher than 250 mg/dl, NOD mice go through a long, clinically
silent period characterized by a leukocytic infiltrate of the pancreatic islets, referred to
as insulitis.

Susceptibility to Type 1 diabetes in NOD mice is polygenic. Currently at least 20
diabetic susceptible alleles have been identified that are associated with the onset and
development of diabetes in the NOD mouse (99). These alleles are highly polymorphic.
This makes it possible to identify the diabetic susceptible alleles with the aid of
microsatellite markers, a group of variable DNA sequences closely linked to the
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diabetic susceptibility loci. By genotyping these diabetic susceptiblity alleles, Serreze et
al. (100) established a successful protocol for producing "speed congenic NOD mice"

from other strains of mice. Since our antioxidant transgenic mice were established and
maintained on the FVB background strain, we utilized Serreze' s procedure to more
rapidly generate new NOD strains homozygous for all NOD susceptibility alleles which
were congenic for our pancreatic beta cell antioxidant transgenes. The susceptibility to
Type 1 diabetes in NOD mice is also significantly affected by environmental factors,
including housing conditions, health status, diet and chemical or virus exposure. The
onset of diabetes in NOD mice is relatively slow and random. The onset of diabetes in
NOD mice is known to be highly variable from one mouse to another. Therefore
cyclophosphamide (CYP), an alkylating cytostatic drug is often employed to speed up
diabetes onset in NOD mice (101). The mechanism for this accelerated diabetes by CYP
is not completely defined but in some studies CYP has been shown to activate the
immune response in NOD mice by suppressing T-helper cells (102). In this project we
injected CYP into our transgenic NOD mice to accelerate and synchronize NOD
diabetes.
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Beta cell death in diabetes

Pancreatic beta cells undergo cell death in both types of diabetes. Type 2 diabetes is
characterized by both insulin resistance and pancreatic beta cell dysfunction, which
leaves the beta cell unable to compensate for insulin resistance with increased insulin
secretion (103). During the development of type 2 diabetes, the normal insulin secretion
of beta cells is impaired and beta cells may eventually undergo degeneration. The
studies in the animal models of type 2 diabetes have demonstrated that beta cell death is
responsible for beta cell failure (104; 105).

Free fatty acids, NO, high glucose and

amyloid polypeptide have been suggested to cause beta cell apoptosis in experimental
type 2 diabetes like situations (106-109).

In type 1 diabetes, the destruction of beta cells is caused by direct interactions with
cytotoxic CD8 (110-112) or CD4 T cells (113), or indirectly via soluble cytokines or
free radicals released by inflammatory cells within the islet lesion (114-116). Beta cell
death could be either through necrosis or apoptosis, which are biochemically and
morphologically distinct. Necrosis is the result of direct toxic or physical injury to tissue.
During necrosis cells swell, the plasma membrane bursts and contents of the cytoplasm
are released. In contrast, during apoptosis programmed cell death is executed through an
intrinsic cascade that triggers cysteine proteases to activate endonucleases, resulting in
DNA fragmentation and associated nuclear and cytoplasmic condensation. There is no
leakage of cellular contents as the plasma membrane remains intact. Apoptosis can
occur in both normal physiological processes such as morphogenesis, homeostatic
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maintenance of tissues and removal of harmful cells (117; 118) and pathological
situations.
Apoptosis has been recognized as the main mode of beta cell death in NOD mice (119).
There are indications that beta cells die by apoptosis in the early stages of human type 1
diabetes (120-122). In cultured human islets cytokines induce mainly apoptosis but not
necrosis (123-125).

Signaling during apoptosis

Cell apoptosis occurs following a cascade of cell signaling and caspase-mediated events.
A diverse group of cell signaling pathways, such as MAP kinase, Akt and NFkappa B ,
have been shown to be involved in regulating pro- and anti-apoptotic protein activity
and expression. Cell fate is thought to be determined by the balance between negative
and positive regulation by these signaling pathways.

It is generally recognized that there are two primary modes of apoptosis induction. One

is extrinsic induction in which apoptosis induced by activation of cell surface receptors
like the Fas or tumor necrosis factor (TNF) receptor, called" death receptors". These
receptors contain cysteine-rich extracellular ligand binding domains, and a cytoplasmic
death domain. After ligand binding, these receptors interact with a variety of death
domain adaptor protein, such as FADD, TRADD and RIP, which can activate caspases,
as well as cell signaling pathways such as the MAP kinase and NFkappa B pathways.
The other route of apoptosis stimulation is through intrinsic induction that occurs via
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the disruption of intracellular homeostasis without involving cell surface receptor. It is
widely reported that many organelles such as lysosomes, Golgi apparatus, endoplasmic
reticulum, and mitochondria contribute to apoptotic cell death (126). Of the organelles
involved in apoptosis, the mitochondria have received the most attention. Mitochondrial
dysfunction causes the release of cytochrome c into the cytoplasm where it binds to
apoptotic protease activating factor 1 (Apaf-l), and triggers the assembly of a complex
called the apoptosome, a multimeric structure composed of cytochrome c, Apaf-l and
ATP or dA TP. The apoptosome at the same time recruits and activates pro-caspase-9
through the Apaf-l caspase recruitment domain. Once activated, the caspase9/apoptosome complex is a stable and potent structure. The primary target of caspase-9
complex is pro-caspase-3, one of the most potent effector caspases in apoptosis.

Regardless of the mode of induction (extrinsic vs. intrinsic), the caspases are
consequently involved in a cascade of cleavage events that result in the initiation and
execution of apoptosis. Caspases are cysteine-containing aspartic acid-specific
proteases that exist as zymogens in the soluble cytoplasm, endoplasmic reticulum,
mitochondrial intermembrane space, and nuclear matrix of virtually all cells (127). In
response to apoptotic stimuli, the initiator caspases, such as caspase-2,-8,-9, and-la, act
as upstream transducers and cleave downstream executioner caspases. The executioner
caspases, such as caspase-3,-6, and -7, ultimately degrade or cleave a variety of other
cellular proteins. One of these proteins is a caspase-dependent endonuclease, which is
freed from its inhibitor by caspase-3 and subsequently cuts DNA into oligonucleosomal
(180-bp) fragments (128).
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Molecular effectors and signaling transduction of pancreatic beta cell apoptosis in
Type 1 diabetes

T cells
It has been established that CD4+ and CD8+ as well as macrophages are needed to

produce insulitis and diabetes in animal models (129). But the precise mechanism by
which these T-cells exert their effector function is not clear. However, convincing
evidence suggests that CD4+ T -cells play an important role in beta cell destruction
during type 1 diabetes. It is unquestionable that CD4+ T cells are both necessary and
sufficient to cause type 1 diabetes in animal models (130; 131). Activated islet specific
CD4+, but not CD8+ cells can transfer diabetes (132). Further, CD4+ T-cells destroy
islet beta-cells in the absence of CD8+ T-cells (133). However, non-activated CD4+ T
cells from prediabetic NOD mice are incapable of transferring diabetes without CD8+ T
cells. Purified CD4+ T cells from young prediabetic NOD mice even inhibit diabetes
transfer by spleen cells from diabetic NODs (134;135). The above data suggest that
CD4+ T -cells probably act as regulatory T cells and their destructive effect on beta cells
seems dependent on the stage of diabetes development.

CD8+ T cells are usually necessary but usually not sufficient to cause beta cell
destruction. CD8+ T cells alone are not capable of transferring diabetes. However, the
development of beta cell specific CD4+ T cells is dependent on prior activation of
CD8+ T cells, because transfer of diabetes by non-activated CD4+ T cells from
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prediabetic NOD mice requires CD8+ T cells (136). Furthermore, CD8+ T cell have a
unique role in the initiation of disease, which can not be performed by CD4+ T cells.
Thus depleting CD8+ T cells using anti-CD8 antibodies retards the development of
diabetes in NOD mice. The above data indicated that possibly CD8+ T cells act by
amplifying CD4+ T cell responses and other inflammatory responses in the infiltrate.
NOD mice homozygous for ~2mnull allele, which are deficient in both cell surface class
I MHC expression and CD8+ T cell, showed no evidence of insulitis nor did they

develop diabetes (137-140). Transfer of diabetes to NOD ~2mnull recipients with spleen
cells from diabetic wild-type NOD mice was significantly delayed compared with
control NOD mice, demonstrating the importance of CD8+ T cells in the effector phase
of autoimmune diabetes.
The mechanism of T cell direct cytotoxicity has been thought to be through Fas/FasL
binding pathway or the perforin and granzyme pathway, which involves the insertion of
tubular perforin complexes into the cell membrane and osmotic cell death. Cell-bound
molecules (such as members of the TNF family) and soluble cytokines are also an
alternative mechanisms used to kill target cells.

Perforin

Perforin is a 534 amino acid glycoprotein, the expression of which is mainly confined to
CD8+ T cells and NK cells. When cytotoxic T cells interacts with a target cell, they
release perforin which permeabilizes cells, allowing granzyme into the cytosol, where it
activates caspase-3 and induces cell death.
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To assess the relative roles of perforin in beta cell destruction, several transgenic mice
have been used. The available in vivo data on perforin are somewhat contradictory and
often model-dependent. Both in transgenic mice expressing the lymphocytic
Choriomeningitis virus glycoprotein under the control of the rat insulin promoter and in
8.3 T cell receptor CD8+ T cell mediated diabetes, beta cell death is perforin
independent (141-144). However, in transgenic mice expressing the Influenza virus
hemagglutinin in beta cells, CD8+ destruction of beta cells is dependent on perforin
(145).

However, in the NOD mouse perforin-mediated lysis of beta cells has been thought to
be a major mechanism of beta cell destruction. Perforin deficient NOD mice develop
insulitis, but diabetes incidence is reduced and delayed (146). The data suggest that
initiation of disease seems not to require perforin-dependent beta cell lysis, however,
perforin appear to be important as an effector mechanism of beta cell destruction in the
NOD mouse. Low diabetes incidence in perforin deficient NOD mice suggests that
other mechanisms are involved in beta cell destruction in the NOD model.

Fas ligand

Fas (CD95!APO-l) belongs to the RNFR family that is able to signal apoptosis through
intracellular death domain. Fas is constitutively expressed on activated lymphocytes in
some mouse organs. Its expression can be up-regulated by the cytokines IFNy, IL-l and
TNFa in various cells lines. FasL (CD95L) is a membrane protein expressed on
activated T cells (147). The FasL binding to Fas leads to activation of intracellular
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signaling pathway results in cell death. It has been suggested that Fas probably play an
important role in beta cell death in type 1 diabetes both in humans and in the NOD
mouse. However, much of the evidence comes from in vitro studies with isolated
human or mouse islets. Cytokines such as IL-l upregulate Fas expression on both
human and mouse beta cells, resulting in apoptosis (148;149). Fas expression in beta
cell has been found to correlate with beta cell destruction in NOD mice (150). However
evidence for these studies comes mainly from immunostaining of pancreas sections that
are difficult to interpret due to the complex composition of infiltrated islets. In contrast,
using flow cytometry to directly identify Fas expressing beta cells in NOD mice, Fas
expression is detected on a limited number of beta cells (1-5%) even in old (> 125 days)
NOD mice, suggesting that at least in the NOD mouse Fas may not be an important
mechanism of beta cell destruction. The more controversial data comes from an in vivo
Fas-deficient NODlpr mice study. These mice lacking Fas did not develop insulitis and
diabetes, and also were resistant to diabetogenic T-cell transferring diabetes (151-153).
However, islets from these NODlpr mice lacking Fas, when grafted into diabetic mice,
are unable to be protected from autoimmune destruction and restore normoglycemia of
the recipient diabetic mice (154). Finally, the apparent controversy was found to be due
to the fact that Fas-deficient NOD mice have abnormal FasL-expressing lymphoid cells
that inhibit the development of diabetes (155). Therefore it still remains to be
determined what the role ofFas is in development of type 1 diabetes.

Cytokines

40

The proinflammatory cytokine IL-l is produced mainly by activated macrophages and
affects nearly every cell type, often in conjunction with other cytokines. IFNy is
produced by T cells and NK cells. IFN production is stimulated by macrophage-derived
cytokines including TNFa, IL-12, IL-18 and by IFNa itself. TNF is a pleiotropic
cytokine, produced mainly by activated macrophages and T cells.

Expression of these cytokines in the islet lesion has been characterized. In early insulitis
in the NOD mouse and the BB rat, expression ofIL-1, TNFa, and IFNy can be detected
(156;157). IL-1 mRNA and protein expression are detected in the infiltrate of islets
from NOD mice (158), as is TNFa (159;160). There is also elevated expression ofIFNy
after 3 months of age in female NOD mice (161;162). The presence of these cytokines
in islets of NOD mice suggests that they may be involved in beta cell destruction and
diabetes.
In vitro study, in rodent islets, IL-l alone or combined with IFNy/TNFa could cause
both necrosis and apoptosis, however, in human islets, a combination of the three
cytokines is required to induce similar cytotoxic effect (163). Furthermore, human beta
cells exposed to cytokines die mainly in a process of apoptosis, whereas beta cell
destruction in rodent islets constitutes a mixture of necrosis and apoptosis.

To address the effector role of cytokines in vivo, systemic administration either anticytokine antibody or cytokines has been used. The data from in vivo studies using
systemic administration of cytokines is contentious.(164). In contrast, the data from
anti-cytokine intervention using antibodies or soluble receptors against IL-l, TNFa and

41

IFNy have almost unanimously shown inhibitory effects on diabetes on NOD mice and
BB rats (165). However, despite these data it remains to be demonstrated whether these
effects are exerted by blocking cytokine action directly on the beta cells or by immune
modulatory effects of these cytokine antagonists (166).

To clarify the more direct role of locally produced cytokines in beta cell destruction, in
the past 10 years, cytokine transgenes have been introduced into beta cells of both nondiabetic-prone animals and NOD mice. In non-diabetes-prone animals, only IFNa/y or
TNFa/B7 transgenic expression produced both insulitis and diabetes. In NOD mice,
overexpression of IL-2 in beta cell could speed up diabetes onset. However,
overexpression of TNFa has shown that the time of TNFa expression is critical in
determining its ability to enhance or prevent the onset of diabetes. Overexpression of
TNFa in beta cells of adult NOD mice leads to rapid infiltration in the islets without
loss of beta cells or diabetes (167). But when TNFa is expressed in beta cells of
neonatal NOD mice diabetes occurs rapidly in all mice (168). This suggested that TNFa
could have very diverse effects depending on the location of action and time window.
Several systemically cytokine-deficient NOD mice also have been used to address the
function of cytokines in NOD diabetes development. Only IFNy receptor a-chain
disruption and IL-l receptor deficiency produce a protective effect, indicating that these
receptors may be playing an important role in the development of diabetes. But
interestingly, IFNy receptor p-chain disruption did not show any protection from
diabetes onset in NOD mice.

42

Overall, although in vitro studies suggest that cytokines either alone or combination
could exert direct destruction effect on pancreatic beta cell, however, the clear
conclusion is still difficult to draw from the above in vivo studies. Since redundancy,
compensatory mechanisms and secondary pathology must be involved in single
cytokine transgenic or knock out model (169), these studies may only provide limited
information on the in vivo relevance of the local role of cytokines as effectors of beta
cell destruction.

Cell signaling pathways

Several signaling pathways and transcription factors have been found to mediate
cytokine signaling in beta cells. IL-l could bind IL-l receptors including IL-IRI and
IL-IR2. The low affinity IL-IRI is the signal-transducing receptor, whereas the high
affinity IL-IR2 is a decoy receptor (170). Since IL-IRI shares no significant homology
with conserved protein kinase domains, it is unlikely to have any intrinsic protein kinase
activity (171) and may need to recruit cytoplasmic proteins to transmit its signals. These
cytoplasmic proteins include IL-I receptor accessory protein (IL-AcP), adaptor protein
MyD88, IL-IRI activated kinase (IRAK) and TNF-receptor-associated factor-6
(TRAF6). IL-l-induced signal transduction involves several major pathways, such as
the activation of PI3K; mitogen-activated protein kinases (MAPK); protein kinase C
(PKC) and transcription factor nuclear factor KB (NFKB) and activator protein-l (AP-l).
NFKB is the main transcription factor for iNOS gene expression, which can cause NO
dependent beta cell destruction.
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TNF receptors include 2 types of receptors, one is the p60 receptor and the other is the
p80 receptor. These two receptors have similar extracellular but different intracellular
domains. P60 receptor cytosolic protein has a death domain which the p80 receptor
lacks. This death domain is considered crucial for transmitting the death signal through
interacting with the TNF receptor associated death domain (TRADD), which in turn
recruits the Fas-associated death domain (F ADD). Finally, TNF receptor associated
factor 2 (TRAF2) will bind to the p60/TRADD/F ADD complex and mediate subsequent
events, such as modulation of c-jun N-terminal kinase (JNK), p38 kinase, PKC, and
transcription factor NFKB.

IFNy signals are through the IFNy receptor I, which subsequently recruits accessory
factor proteins (IFNy receptor 2). Once they associate together, a cytosolic protein
kinase called Janus tyrosine kinase I and 2 (JAKII2) are activated by autophosphorylation and transphosphorylation. JAKII2 will further activate transcription
factor STAT! through phosphorylation. Activated STAT! will trans locate to the
nucleus inducing gene expression such as caspase expression, thereby inducing a proapoptotic response (172).

Among these signaling pathway induced by cytokines, it should be noted that cytokine
not only induced death signal such as activation of JNK, p38, AP-I, it also induced
survival and cell defense signal such as PI3K1Akt, ERK pathway, which indicates that
balance among those different pathway will finally determine the beta cell fate.
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ROS and cell signaling

ROS are species of oxygen which are in a more reactive state than molecular oxygen,
and in which, the oxygen is reduced to varying degrees. ROS from mitochondria and
other cellular sources have been traditionally regarded as toxic by-products of
metabolism with the potential to cause damage to lipids, proteins, and DNA (173).
However, more and more, recent evidence suggests that ROS are not only injurious byproducts of cellular metabolism but also essential participants in cell signaling and
regulation (174;175). This apparent paradox in the roles of ROS as essential
intracellular signaling molecule and as toxic by-products of metabolism probably
partially depends on the different concentration and cellular sources of ROS generation.
The typical example is the effects of nitric oxide, which has both regulatory functions
and cytotoxic effects depending on the enzymatic source and relative amount of NO
generated (176). NO could function as a signaling messenger if produced in low
concentrations by the constitutive isoform of nitric oxide synthase (NOS) in endothelial
cells or neurons, and also as a toxic product with potential to cause damage to tissue if
produced in high concentrations (two or three orders of magnitude higher) by the
inducible NOS in macrophages and other immune-effector cells. This dichotomy
between signal transduction and toxic function is likely to be preserved for other
reactive oxygen species such as hydrogen peroxide and superoxide.
However, to be considered as a potential signaling molecule, ROS must: 1) be produced
by a cell when stimulated to do so; 2) have an action in a cell, either the cell which
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produces it or a nearby cell; 3) be removed in order to tum off, or reverse, the signal. It
is now clear that some ROS, particularly hydrogen peroxide (H 20 2) and superoxide,
fulfill these criteria. Hydrogen peroxide is a small, diffusible, and ubiquitous molecule
that can be synthesized, as well as destroyed, rapidly in response to external stimuli. It
has been shown that H202 can mimic the stimulatory effects of insulin on glucose
transport and lipid synthesis in adipocytes (177). It has been well demonstrated that
ligand stimulation of non-phagocytic cells results in an increase in intracellular ROS.
This phenomenon has been observed in a wide variety of cell types and is stimulated by
a diverse collection of ligands, including cytokines (178-180) as well as peptide growth
factors acting through tyrosine kinase (181-184) and G-protein-coupled receptors (185).

Cellular sources of ROS

Any electron-transferring protein or enzymatic system can result in the formation of
ROS. Therefore both enzymatic and nonenzymatic sources contribute to total cellular
ROS generation. It has been proven that ROS can be generated in cells by several
pathways.

Mitochondrial
Cellular energy metabolism is based on the production of ATP through the electrontransport reaction in which O2 accepts electrons and H+ and then is reduced to water.
During this process, leakage of a single electron being transferred to O2 could result in
the production of O2-. Mitochondria normally consume the vast majority of O2 to
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generate ATP through the respiratory chain. However, 1-2% of electrons are leaked to
generate O2- in reactions mediated by coenzyme Q and ubiquinone and its complexes
(186; 187). Thus mitochondria are believed to be a major site of ROS production in vivo
(188). NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase, which
contain ubisemquinone as an important constituent, were shown to generate superoxide
and hydrogen peroxide (189). The potential for mitochondrial ROS to mediate cell
signaling has gained significant attention on the regulation of apoptosis (190-193).
Some studies suggest that TNFa and IL-1 induced apoptosis may involve mitochondria
derived ROS (194-196). It also has been found that mitochondrial ROS could trigger
hypoxia induced transcription (197; 198).

Edoplasmic reticulum (ER)

ER is another membrane bound intracellular organelle that is primarily involved in lipid
and protein biosynthesis. In ER, superoxide could be generated by the leakage of
electrons from NADPH cytochrome p450 reductase (199). Although there is no direct
link between ER derived oxidants and cellular signaling, there is evidence for redox
regulation of ER related protein folding and secretion (200-202).

NADPH oxidase

NADPH oxidase is a plasma membrane associated oxidase. In phagocytic cells, it has
been well characterized that NADPH oxidase serves a specialized function in host
defense against invading microorganism(203;204). Activated macrophages and
neutrophils can produce large amounts of superoxide and its derivatives via the

47

phagocytic isoform of NADPH oxidase. This multicomponent enzyme consists of the
membrane-bound cytochrome b ss 8 complex comprising gp91 phox and p22 phOX, the
cytosolic proteins p47 and p67, and a low molecular-weight G protein of the rac family.
Phagocytic NADPH oxidase becomes activated upon translocation of cytosolic p47,
p67 and a G protein of the rac family to the membrane-bound cytochrome b ss8 complex.
Activated enzyme catalyzes the the one-electron reduction of 02 to 02-', with NADPH
as the electron donor through the transmembrane protein cytochrome b ss 8. The
activation of phagocytic NADPH oxidase can be induced by microbial products such as
bacterial lipopolysaccharide, by lipoproteins, or by cytokines such as interferon-y,
interleukin-l ~ or interleukin-8(205). The activation of NADPH oxidase is mainly
controlled by the rac isoform rac2 in neutrophils and rac 1 in macrophages and
moncytes(206;207).

Nonphagocytic NAD(P)H oxidases have been implicated as the sources of growth
factor and lor cytokine stimulated oxidant production(208-212), which plays a role in
the regulation of intracellular signaling cascades in various types of nonphagocytic cells
including fibroblasts, endothelial cells, vascular smooth muscle cells, cardiac myocytes
and thyroid tissue(213-221). Rac1 also has been found to be involved in the induction
of NADPH oxidase activity. Angiotensin II increases NAD(P)H driven superoxide
production in cultured vascular smooth muscle cells and fibroblasts. Thrombin PDGF,
and TNFa stimulate NAD(P)H oxidase dependent superoxide production in vascular
smooth muscle cells. IL-l and TNFa increase NAD(P)H dependent superoxide
production in fibroblasts.
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However, compared with phagocytic cells, the rate of superoxide production in
nonphagocytic cells is much lower, only about one-third of that of neutrophils. Unlike
neutrophils, some nonphagocytic cells such as vascular smooth muscle cells generate
superoxide and hydrogen peroxide mainly intracellularly.

Xanthine oxidase

In addition to intracellular membrane-associated oxidases, soluble enzymes such as
xanthine oxidase, aldehyde oxidase, dihydroorotate dehydrogenase, flavoprotein
dehydrogenase and tryptophan dioxygenase can generate ROS during catalytic cycling
(222). The most extensively studied of these is xanthine oxidase, which generates
superoxide by converting hypoxanthine into xanthine and xanthine into uric acid.
Xanthine oxidase is derived from xanthine dehydrogenase by proteolytic cleavage(223).
Under normal conditions, xanthine oxidase accounts for only a minor proportion of total
ROS production(224). However, there is evidence that TNF treatment induced ROS
production in endothelial cells could be through xanthine oxidase(225). Some other data
suggest that ROS produced by xanthine oxidase has been implicated as a major souce
of oxidative stress under pathological conditions such as ischemia and reperfusion(226).

Other source of ROS

In addition to several sources of ROS described here, there are various other enzymic
and

nonenzymIc

mechanisms

of ROS
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production

such

as

Lipoxygenase,

cyclooxygenase and dopamine, it has been shown that cytokines such as IL-l or TNF a
could induce ROS production through lipoxygenase or cyclooxygenase (227;228).

Signaling molecules targeted by ROS

Protein Tyrosine Kinases and Phosphatases
Although ROS are involved in regulating many signaling pathways, the signaling
molecules targeted by ROS have remained largely unexplored. However, lots of
evidence suggests that ROS regulation could occur at multiple levels in the signaling
pathways from receptor to nucleus.

Protein Tyrosine Kinases and Phosphatases
There are various examples of growth factors, cytokines, or other ligands that trigger
ROS production in nonphagocytic cells through their corresponding membrane
receptors. Such ROS production can mediate a positive feedback effect on signal
transduction from these receptors through upregulating protein phosphotyrosine.

Reversible protein phosphorylation is the key biochemical event in most cell signaling
pathways. In general, the upregulation of phosphotyrosine signaling by oxidants may be
rationalized in terms of two different effects: the inhibition of protein tyrosine
phosphatases(PTPs) and lor the activation of phosphotyrosine kinases. Actually, some
studies have shown that both phosphotyrosine phosphatases and kinases may be targets
of oxidative stress. But it is still unclear which one is predominant.
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ROS could reversibly inactivate PTPs and / or protein phosphatase A by the direct
oxidation of cysteine in the active site of these enzymes. (229) All PTPs share a
common and also essential catalytic cysteine residue in their active sites, which is
extremely reactive,

with a lower pKa (about 5.5) than the pKa (about 8) of other

cysteine residues in most proteins(230). The low pKa makes the thiolate anion
especially susceptible to the inhibitory action of ROS by forming a sulfenic acid (CyssOH) intermediate. This transient intermediate could be reversed by a thiol-reducing
agent such as glutathione. It has been reported H202 treatment could inhibit PTPs in
vitro (231) as well as in several cell lines such as M07e (232), HER14 cells(233),
Jurkat T lymphocytes(234) and HELA cells(235). Antioxidants such as Nacetylcysteine (NAC) inhibits H202-induced phosphatase inactivation in glia cell
lysate(236). Since the fully active PTPs can efficiently remove phosphotyrosine
residues and destroy binding sites for other signaling molecules shch as PI3-kinase,
ROS inactivation of PTP could enhance tyrosine receptor induced downstream cellular
signaling. Because the level of tyrosine phosphorylation of cellular proteins is
determined by the balance of PTK and PTP activity, oxidant induced inactivation of
PTPs results in an apparent enhancement of tyrosine phosphorylation.

Although activation of PTK by ROS could be the consequence of ROS inhibition of
PTPs, however, recent data also suggested that ROS might directly affect some
cytoplasmic PTK activation such as src family tyrosine kianses(237;238). The src
family of tyrosine kinases is a closely related groupd of nonreceptor kinases involved in

51

signaling pathways that, in response to the activation of cell-surface receptors by
growth factors, cytokines, or cell-surface ligands, control the growth and differentiation
of cells(239).
Both in vivo and in vitro studies have been shown that NO and a relatively low
concentrations «1 00

~M)

of peroxinitrite could directly increase c-src activation while

high concentration of peroxinitrite inactivate c-src. (240;241). ROS such as NO and
H202 might react with thiol group of Src molecules to form disulfides (s-s) bond,
which destabilize the Src structure for Tyr-416 autophosphorylation-associated
activation. Such NO activated Src kinase will be abolished when treated with reducing
agents such as 2-ME and dithiothreitol, which should interrupt the the NO mediated SH
group modification forming S-S bond(242).

Therefore, upregulation of tyrosine phosphorylation by ROS through PTP inhibition is a
plausible cellular event, but PTP inhibition can not be the sole mechanism and
activation of PTK by ROS might be an alternative mechanism.

Serine/Threonine Kinases and Phosphatases

The MAP kinases belong to a large family of praline-directed serinlthreonine kinases
including extracellular signal regulated kinase (ERKs), c-Jun N-terminal kinase (JNK)
and p38 MAPK (p38). Many studies have shown that addition of exogenous H202, and
exposure to radiation or to drugs known to induce production of H202, such as
menadion, lead to activation of the MAP kinase including a new family member, Big
MAP kinase

I(BMK1)(243-248).

The mechanisms by which exogenous or
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endogenously produced ROS activate the MAP kinases are not well defined. Several
studies suggested that ROS activate MAP kinase cascade through a Ras-dependent
mechanism(249-251). Ras, a small G protein, could be directly altered by oxidation of a
cysteine close to the guanine nucleotide binding site, resulting in activation(252-254).
Also activation of the MAP kinases could be the result of activation of the Src kinase
family. Since c-Src was found to be required for the H20 2 and UV induced activation of
JNK(255;256) and H202 induced activation of ERK5(257;258). Another mechanism
has been proposed for JNK and p38 activation that involved ROS-dependent
dissociation of a signalosome that maintains the pathway in an inactive state. ASK1, a
MAPKKK for JNK and p38 associates with reduced thioredoxin (Trx) in non-stressed
cells. Oxidation of Trx by ROS releases ASK-1, and leads to JNK and p38
activation(259). ASKI knockout mice exhibited lower levels of JNK and p38 activation
in comparison to wild type after H202 or TNFa stimulation(260).

Other serine/threonine kinases such as Akt and PKC also have been found to be
activated by ROS. Treatment of cells with H202 leads to the activation of Akt
(261 ;262).Akt is a pleckstrin-homology domain containing serine/threonine kinase.
Since Akt activity is stimulated by growth factors through the activation of PI3kinase(263-265), it is possible that H202 enhanced PTK induced downstream cellular
signaling results in Akt phosphorylation and activation.

PKC is involved in signal transduction to vanous effector pathways that regulate
transcription and cell cycle control. This enzyme is typically activated by the lipid
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second messenger diacylglycerol(266;267). However, treatment of cells with H202
could lead to activation of PKC in a phospholipids independent process that involves
tyrosine phosphorylation in the catalytic domain(268;269). To search for the possible
mechanism, a study using purified PKC reavealed that selective oxidative modification
at the amino-terminal regulatory domain, which contains a zinc-thiolate structure,
generated activated PKC(270) . In contrast, oxidative modification at the carboxylterminal catalytic domain resulted in complete inactivation of the kinase(271). Thus
oxidants appear to directly regulate PKC activity in the dual manner. Other studies
suggested that ROS also could modify some phospholipids metabolites such as
diacylglycerol to affect PKC activation(272;273). Takekoshi et al showed that the
oxidized forms of diacylglycerol were more effective in activating PKC than its
nonoxidized forms(274).

It should be noted that ROS could regulate serine/threonine phosphatases activity.

Studies in vitro revealed that thiol oxidation of protein phosphatase 1 and 2A inhibited
the enzymic activity(275).

Ca2+ signaling
Changes in the cytosolic Ca2+ level play a role in the modulation of several
intracellular signal pathways, including PKC and calmodulin-dependent signal
pathways(276). Oxidative radical stress could increase cytosolic Ca2+ level through the
mobilization of intracellular Ca2+ stores and lor through the influx of extracellular
Ca2+(277-281). Oxidant-induced Ca2+ mobilization is blocked by herbimycin A, a
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PTK inhibitor(282;283) and is partly suppressed in mutant cells that do no express Syk
or Lyn(284;285). This suggests that the intracellular Ca2+ level is regulated by ROS
probably through the activation of upstream PTKs. Furthermore, this ROS-mediated
increase in the cytosolic Ca2+ level could contribute to the oxidative stress-mediated
activation of PKC(286) and to the transcriptional induction of the AP-l (287;288).

Redox regulation of Transcription factors such as NF -KB, AP-l, HIF, p53, et al

NF -KB, a transcription factor that regulates the expression of a number of genes
involved in immune and inflammatory responses, stress response, cell growth and cell
survival, has long been considered oxidant responsive(289;290). It is the first eukaryotic
transcription factor shown to respond directly to oxidative stress in certain types of
cells(291). However, the mechanisms by which ROS regulate this activity have
remained elusive. Recently, some evidence suggested one possible mechanism
contributes this effect. This mechanism involves the oxidative enhance of upstream
signal cascades, which could result in increasing phosphorylation of IKB, a critical step
in NF-KB activation. IKB has been well known an endogenous inhibitor for NF-KB
activity. Once IKB is phosphorylated, it is rapidly degraded in proteasome dependence.
Exposure to 300 IlM H202, increased phosphorylation of IKBcx was found in EL4 T
cells(292), and similar induction of IkB phosphorylation was seen in Jurkat T cells after
a mild oxidative shift in the intracellular thiol pool(293).

Activator protein-l (AP-l), a transcriptional complex typically composed of c-Fos and
c-Jun preteins, has also been demonstrated to be regulated by redox mechanisms. Many
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different oxidative stress-inducing stimuli, either exogenous oxidants such as relatively
low concentrations of hydrogen peroxide, UV light, y-irradiation or ligand induced ROS
such as interleukin-l treatment, lead to AP-l activation(294-298). The activity of AP-l
has been revealed to be regulated by redox through the conserved cystein residues that
are located in the DNA binding domain of each Fos and Jun protein(299;300). The
modification of these residues by a sulfhydryl modifying agent, such as Nethylamaleimide(NEM) or diamide, reduce its activity, whereas treatment with
reductants, such as dithiothreitol (DTT), enhance DNA binding. Further evidence
suggests that the redox regulation of AP-l DNA binding is facilitated by the reducing
activity of redox factor-l (Ref-I) protein that may act directly on this critical cysteine
residue(301). Other transcription factors such as c-Myb, p53, Sp-l have similar redox
mechanism to regulate their DNA binding(302-304).

Mechanisms of ROS signaling action

Oxidative modification of proteins
The chemistry of ROS suggests that ROS could primarily react with some amino acid
residues such as cystein residues and protein bound metals, including heme iron.
Oxidative modifications of some critical amino acids within the functional domain or
regulation domain of protein may alter protein structure and function. By far, the best
described of such modifications involves cysteine residues. Signaling proteins
containing cysteines have been suggested as targets for ROS. The sulfhydryl group (SH) of a single cysteine residue may be oxidized to form sulfenic (-SOH), sulfinic (-
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S02H) or sulfonic (-S03H). Formation of the latter two compounds is essentially
irreversible and therefore unlikely involved in signaling. Although these reducible
forms are often considered as the mediators of redox signaling(305;306), not all
cysteine residues are equally susceptible to reaction with ROS. As the pKa of most
protein cysteine residues is around 8.3, they remain protonated at physiological pH.
Thus the reaction rate of most protein cysteines with ROS is too slow to be of
physiological relevance. However, this situation is dramatically altered when cysteine is
bound to a metal(307) or is in the thiolate anion (-S-) form. The resulting thiolate can
then react rapidly with H202 to form sulfenic acid. The typical example is PTP, which
has already been mentioned before. With pKa <6, the catalytic site cysteine residue of
PTP is extremely reactive and rapidly forms a thiolate anion at physiological pH, and
could be easily oxidized by ROS.

Two or more cysteine residues within the same protein may be oxidized to form an
intermolecular disulfide bridges, thereby altering its conformation and regulating its
activity. The studies of bacteria transcritption factor OxyR have provided the wellestablished example of oxidative stress response activation by disulfide bond formation.
The transcription factor OxyR could be activated by ROS and trigger the expression of
defense activities including superoxide dismutase and peroxidase. H202 can act
directly on OxyR, generating a reactive oxidized derivative of a cysteine within the
protein, which then can form a disulfide bond. Alternatively, OxyR can be activated by
disulfide bond formation resulting from the altered redox state of the cytosol(308;309).
Thioredoxin (Trx) also has a propensity for forming an intramolecular disulfide which
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has been shown to be involved in redox signaling. The Trx family has a conserved
catalytic site, called a thoredoxin fold, with two close cysteine residues, one of which is
a thiolate. An intramolecular disulfide can be easily formed if one of them is oxidized
to a sulfenic acid. One example of signaling role for Trx is that Trx could regulate the
activity of signaling kinase ASKl, one of the MAP kinase kinase kinases upstream of
JNK, through its reversible oxidation(310). This study has shown that Trx is an
inhibitor of ASKI by binding to its amino-terminal domain that both TNFa and ROS
activate ASKI by inducing dissociation of Trx. Some evidence suggest that with
respond to oxidant stress, Trx could translocate from the cytosol to the nucleus to bind
and activate transcription factor NFKB or Ref-I, whose activation facilitates other
transcription factors DNA binding to mediate transcription(311 ;312).

Finally, two identical or different proteins containing cystein residues also can be
oxidized by ROS to form intermolecular disulfide bonds and result in homodimerization
or heterodimerization reactions, therefore regulating their function.

Alteration in intracellular redox state
Redox state is a term that has historically been used to describe the ratio of the
interconvertible oxidized and reduced form of a specific redox couple. Recently
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biological research, it generally describes an indicator of the redox environment of cell.
And it also can be used to correlate with several aspects of cell signaling (313). In
several cases, changes in the intracellular thiolldisulfide redox state have been shown to
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trigger the same redox-responsive signaling proteins and pathways as those triggered by
H202(314-317).

The cellular cytosol is normally maintained under strong "reducing" conditions. There
are many redox couples such as GSSG/2GSH couple and TrxSS/Trx(SHh couple in a
cell that work together to maintain the redox environment. Glutathione(GSH) is
considered to be the major thiol-disulfide redox buffer of the cell. Therefore, the
GSSG/2GSH couple is the most abundant redox couple in a cell. Many researchers
estimate the redox state of the system by taking the ratio of [GSH]/[GSSG]. Changes of
the half-cell reduction potential (Ehc) of the GSSG/2GSH couple appear to correlate
with the biological status of the cell: proliferation Ehc =:::-240 mV; differentiation E hc ::::::200 m V; or apoptosis Ehc :;:;-170 m V (318).

Trx is another important thiol-system in the cell. Its level is 100 to 1000 fold less than
GSH. As mentioned before, it reduces cystine residues in the DNA-binding sites of
several transcription factors and is therefore important in gene expression(319;320). In
contrast to the small-molecule GSH that forms intermolecular disulfides, Trx is a
protein that usually forms intermolecular disulfides. The reduction of the disulfide back
to the dithiol form is catalyzed by Trx reductase, the source of electrons being
NADPH(321 ;322).

ROS and type 1 diabetes
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It is general believed that ROS contribute to autoimmune mediated beta cell destruction.

Since ROS are so essential in autoimmune diabetes, on the other hand, pancreatic beta
cell contain extremely low ROS scavenge system, many trials using antioxidants to treat
diabetes and prevent beta cell damage have been performed in both in vitro and in vivo
studies. In vitro most of beta cell tumor lines studies provide pretty consistent results
that antioxidants provide protection from ROS and cytokine induced toxicity(323-327).
However, the relevance of these antioxidant protective results from beta cell tumor lines
is still uncertain due to the difference between primary beta cells and tumor cell lines. It
has been shown that treatment of isolated islets with antioxidants do not always reduce
cytokine toxicity(328). Systemic treatment with antioxidants is most often performed in
vivo. However, the major ambiguity in those in vivo studies is the site of protection.
The protection of delaying diabetes onset with systemic antioxidant treatment could be
produced at the immune system rather than directly at pancreatic beta cells(329). The
studies for the proposal where antioxidant treatment has been directly targeted to beta
cells are not only limited but the results are also controversial. Adenoviral expression of
MnSOD was partially effective against cytokines in isolated primary islets(330).
However, beta cell specific overexpression of the secreted form of SOD had no effect
on NOD diabetes(33l). Thioredoxin overexpression in beta cell delays NOD diabetes
onset(332), but thioredoxin has an additional very potent anti-apoptotic effect, which
may contribute to this significant benefit.
Therefore, it is still not clear what roles ROS play in type 1 diabetes. To provide more
detail and specific analysis, we employed NOD mice with specifically overexpressing
three antioxidants including MnSOD, catalase and MT in pancreatic beta cells. These
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three antioxidant proteins have been shown to be able to scavenge many types of ROS
and protect from STZ or hypoxia induced beta cell damage(333-335). However,
unexpectedly two cytoplasm antioxidants, catalase and MT, but not mitochondrial
MnSOD, dramatically hastened both spontaneous and cyclophosphamide induced
diabetes onset in NOD mice.

This result suggests that the role of ROS

IS

more

complicated than previously proposed and normal cytoplasmic ROS may be necessary
to trigger beta cell self protective response during autoimmune type 1 diabetes.

Potential mechanism by which antioxidants could sensitize to diabetes in NOD

Most studies dealing with the pathogenesis of IDDM have emphasized the immune
assault against beta cells. However, there are many evidences that suggested that the
beta cell destruction of IDDM depends on a balance between beta cell damage and
repair/regeneration. The progressive beta cell damage leading to IDDM seems to follow
markedly different temporal courses in individual patients. Some individuals at high
risk for developing IDDM, and presenting with impaired beta cell function, appear to
recover beta cell function when followed prospectively. Moreover, after the clinical
onset of IDDM, most patients experience a transitory period of improved insulin
secretion. In vitro and in vivo experimental data suggest that beta cells are indeed able
to repair themselves after damage(336). Diabetes in the NOD mouse can be reversed for
extended periods of time by the administration of anti-CD3(337). Dispersed beta cells
or whole islets can survive and regain their function after a toxic assault. Furthermore,
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the abnormal insulin release and glucose oxidation of islets isolated from NOD mice
during the prediabetic period is completely restored after 1 week in tissue culture (338).

In NOD mice, beta cell proliferation indeed has been found to be increased before
diabetes onset although beta cell mass is continuously reduced (339), which suggests
that hyperglycemia in type 1 diabetes probably results from a long-term negative
balance between immune-mediated beta cell damage and beta cell repairlregeneration.

More and more evidence suggests that apoptosis is the main mode of beta cell death in
early type 1 diabetes. However, apoptosis is a highly regulated form of cell death,
affected by both extracellular signals and intracellular ATP levels, and expression of
apoptotic and antiapoptotic genes and proteins(340). Beta cell programmed death also
emphasizes that it is the beta cell itself that make the final decision for beta cell survival
or death in the early type 1 diabetes(341).

During the early type 1 diabetes, it is certain that immune attack triggers death signaling
pathways in pancreatic beta cells, on the other hand, immune stress also induces some
survival signaling pathways(342).

Some signaling pathway by which extracellular stimuli suppress apoptosis has been
characterized. Survival factors, such as insulin-like growth factor (IGF), bind to their
cell surface receptors trigger receptor autophosphorylation and the activation of receptor
kinase. Cellular scaffold proteins such as insulin receptor substrate (IRS) bind to the
autophosphorylation sites and are phosphorylated on multiple tyrosine residues by the
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activated receptor kinase. Phosphoylated IRS proteins couple IGF receptors to the PI3K
and extracellular ERK cascades. In mice, there are at least three IRS proteins including
IRS-l and IRS-2, which are expressed in pancreatic beta cells. All IRS proteins contain
an NH2-terminal PH domain adjacent to a PTB domain, followed by a variable length
COOH-terminal tail with numerous tyrosine phosphorylation sites.

In pancreatic islet, recent data has reported that Irs-2 branch of insulinJIGF signaling
playa key role in beta cell survival and function (343;344). In mice, both Irs-l knock
out and Irs-2 knock out are markedly induced insulin resistant, however, only Irs-2
knock out mice fail to sustain compensatory insulin secretion due to decreased beta cell
mass compared with wild-type and Irs-l knock out mice and eventually developed
diabetes. In contrast, overexpression of Irs-2 prevents diabetes in Irs2 knock out mice,
obese mice and streptozotocin treated mice (345). This data suggested that the
convergence of peripheral insulin resistant and islet defects around the Irs-2 branch of
the insulinJIGF signaling pathway may reveal the common pathway to diabetes.

Irs-2 branch of insulinJIGF signaling promote cell survival at least in part by activating
the PI3K and its downstream target Akt. PI3K is recruited and activated via
phosphorylated IRS protein interaction. Products of PI3K attract several serine kinases
including Akt and phosphoinositide-dependent kinase(PDK1I2) to co-localize at the
plasma membrane. Akt will be activated through phosphorylation by PDK. One
function of Akt is to phosphorylate and inhibit proapoptotic components of the intrinsic
cell death machinery present within the cytoplasm including Bad, Caspase 9, and
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Forkhead transcription factors such as FKHRLl, Foxol and AFX. It has been shown
that Akt activity is both necessary and critical for beta cell survival. Mice lacking Akt2
produce insulin resistant and pancreatic beta cell failure and loss, which finally result in
severe diabetes(346). Increased expression of Aktl in pancreatic islets protects from
STZ induced diabetes and against free fatty acid induced beta cell apotosis(347;348).
Activation of Akt by IGF protects islets from cytokine toxicity(349;350) and delays
NOD type 1 diabetes onset(35 1).

This insulin! IGF signaling pathway could be turned off by protein tyrosine phosphatase
(PTP). The fully active PTPs can efficiently remove phosphotyrosine residues and
destroy binding sites for other signaling molecules such as PI3-kinase. Inhibition of
PTP will increase activity of insulin!IGF signaling and improve survival. PTP inhibitors
such as vanadate have been tried to treat insulin resistant in type 2 diabetes. Recently it
was also found that diabetes in mice lacking IRS2 could be reversed by crossing with
PTPIB knock out mice(352), indicating that specific phosphatase inhibitors might be
useful treatments for diabetes. Therefore finding an endogenous inhibitor for PTP might
provide an insight for this therapy.

PTPs contain an essential catalytic cysteine residue in their active sites, which is
extremely reactive, with a lower pKa (about 5.5) than the pKa (about 8) of other
cysteine residues in most proteins (353). The low pKa makes the thiolate anion
especially susceptible to the inhibitory action of ROS by forming a sulfenic acid (CyssOH) intermediate. This transient intermediate could be reversed by a thiol-reducing
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agent such as glutathione. It has been reported H202 treatment could inhibit PTPs in
vitro(354) as well as in several cell lines such as M07e(355), HER14 cells(356), lurkat
T lymphocytes (357) and HELA cells(358). Antioxidants such as N-acetylcysteine
(NAC) inhibits H202-induced phosphatase inactivation in glia cell lysate(359). More
importantly, once insulin receptor(360) or EGF receptor (361) was triggered,
endogenous ROS would be produced and inactivate PTPIB, indicating that inhibition of
PTPs by ROS may be a physiologically important event during cell signaling. Catalase
had been proven to abolish insulin-stimulated production of H202 as well as inhibition
of intracellular PTPs (362).

Overall, the insulinlIGF signaling pathway is activated by tyrosine phosphorylation of
the insulinlIGF receptor and key post-receptor substrate proteins and balanced by the
action of specific PTP. PTP activity, in turn, is highly regulated in vivo by
oxidationlreduction reactions involving the cysteine thiol moiety required for catalysis.
Our antioxidants overexpression may disrupt this balance through protecting PTP from
inhibition of ROS.

Hypotheses

It is undoubted that cytokine could produce intracellular ROS. IL-l beta also has been
shown to activate and phosphorylate Akt in several cell types(363-365) as well as in
mouse islet (366). Therefore, we hypothesize that during immune attack the beta cell in
NOD mice is exposed to many stressors including lymphocytes and cytokines, in
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response pancreatic beta cell will first trigger defense system through activating Irs-2
related Akt pathway.

ROS may play an important role during this cell survival

signaling. Our antioxidant transgenes scavenger this minimal ROS and disrupt this
defense system.

Both MT and Catalase transgenes had no deleterious effect on the beta cell structure or
function either in FVB background or in NOD mice at the young age

« 42 days).

Therefore we suspect such ROS regulation in survival pathway of pancreatic beta cells
is more important in pathological situation such as autoimmune attack in type 1 diabetes
than in physiological situation.
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New Hypothesis
limited ROS are essential for pancreatic
diabetic stress.
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survival during

MATERIALS and METHODS
Chemicals:

Collagenase

(type

V),

Glutathione

peroxidase

from

bovine

erythrocytes, H 20 2, hypoxanthine, xanthine oxidase, 3-morpholinosydnonimine (SIN1), S-nitro-N-acetyl-penicillamine

(SNAP), and streptozotocin were bought from

Sigma (St. Louis, MO). Hank's balanced salt solution (HBSS), RPMI 1640 medium,
fetal bovine serum (FBS) and PCR reaction reagents (including Platinum Taq DNA
polymerase, dNTP, Tris PCR buffer and MgCh) were supplied by Invitrogen
(Carlsbad, CA).
I09 cadmium

Proteinase K was purchased from Qiagen

(Valencia, CA) and

was from Amersham (Piscataway, NJ). Rat insulin standard was bought

from Linco (St. Charles, MO). 5- (6)-chloromethyl-2', 7'-dichlorodihydrofluorescein
diacetate (CM-H2DCFDA), picogreen was purchased from Molecular Probes (Eugene,
OR). Alarma Blue was bought from Biosource International (Camarillo, CA). Rabbit
antiserum to guinea pig insulin, was purchased from BioGenex (San Ramon, CA).
Mouse anti-horse MT antibody was supplied by Dako (Carpinteria, CA). Sheep anticatalase and anti-human SOD antibody was bought from Biodesign International (Saco,
Maine). For construction of the transgene enzymes were obtained from New England
Biolabs (Beverly, MA). Other non-indicated reagents were standard chemicals from
Sigma (St. Louis, MO), Fisher Scientific (Pittsburgh, PA) or Amersham Biosciences
(Piscataway, NJ).

Solutions: The following solutions, very commonly used in this project, will not be
further described wherever they were used. They are islet culture medium (with or
without phenol red) (RPMI 1640 medium supplemented with 10 % fetal bovine serum
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plus 100 U/ml penicillin and 100 !Jg/ml streptomycin), modified KRB buffer (KrebsRinger bicarbonate buffer, containing the designated concentration of glucose and
supplemented with 0.1 % BSA and 10mM Hepes, pH 7.4), islet sonication buffer
(lOmM Tris/HCI, pH 7.0, 1mM EDTA, 1mg/ml RIA grade BSA,), acid ethanol for islet
insulin extraction (75 ethanol I 2 concentrated (12 M) HCI I 23 H20, v/v/v), islet DNA
digestion buffer

(0.1 M Tris/HCI, pH 8.5, 5 mM EDTA, 0.2 % SDS, 200 !Jg/ml

proteinase K), Tris-acetate-EDTA (TAE) buffer for electrophoresis (0.04 M Tris/HCI,
0.001 M EDTA, pH 8.5).

Animals: All mice were housed in ventilating cages at the University of Louisville,
Research Resource Center with free access to tap water and standard mouse chow. All
animal procedures were approved by the Institutional Animal Care and Use Committee.
The laboratory was certified by the American Association of Accreditation for
Laboratory Animal Care. The presence of transgenes in transgenic mice was determined
by PCR of mouse tail DNA and/or by observation of coat color which was a product
from a co-injected second transgene tyrosinase.

Maintenance of NOD mice and generation of transgenic NOD strain congenic
for transgenes:

MT, catalase, MnSOD transgenic mice were established in our

laboratory on the FVB strain with pancreatic beta cell overexpression of the human MT
II gene, rat catalase and human MnSOD. In more detail, the construct of MT transgenic
mice was described in the above method and material of Chapter I. The catalase
trans gene, designated Cat, was constructed in a plamsid pKS/RIP provided by Dr.
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Fatima Bosch (Barcelona, Spain) as described previously(367). This gene contained the
rat insulin I promoter linked to 1.8 kb BamHI/Xho I fragment of the rabbit beta globin
gene that included the last beta globin intron and the globin polyadenylation sequence.
An SV -40 enhancer sequence was contained in the downstream portion of the gene. The
catalase cDNA was inserted into a unique Eco RI site of pKS/RIP located 45 bp
downstream from the rabbit beta globin intron. The rat catalase cDNA contained the
entire 1581 bp catalse coding sequence and was cleaved from the transgene MyCat(368)
with Sal I and Hind III. The termini of the catalase fragment were converted to Eco RI
sites by blunt ending and ligation to Eco RI linkers. The 4250 bp transgene was
removed from the plasmid sequences by cutting with Xho I and Sac I. The MnSOD
transgene, designated as MnSOD, was constructed in the same plasmid pKS/RIP by
replacing the catalase cDNA with a full length human MnSOD cDNA.
NOD mice purchased from Jackson Laboratory (Bar Harbor, Maine), were housed
III

individually ventilated microisolator cages at the Research Resource Center in

University of Louisville. Strict cage changing and animal handling procedures were
carried out to minimize viral infection.

The standard mouse chow was Laboratory

Rodent Diet 5001 (PMI Feeds, St. Louis, MO) containing 23% protein and 4.5% fat.
This diet was suitable for maintaining a high incidence of diabetes in NOD mice.
Transgenic NOD mice with beta cell specific expression of MT, catalase and MnSOD
were generated from our transgenic FVB mice using a speed congenic procedure
described by Serreze, et al. (369). In details, the MT, catalase and MnSOD transgenic
th

FVB mice were backcrossed to NOD mice for up to 10 generations. Since the 5 or

i

h

generation, PCR based genotyping with the aid of micro satellite markers was performed
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to find a founder animal congemc for both transgene and all 19 NOD diabetic
susceptible alleles. This animal was used as the progenitor for additional one or two
backcrosses to NOD mouse for more homozygosity of NOD mouse genome. The
produced transgenic and nontransgenic NOD offspring were intercrossed to generate
animals which were used in this study.

peR typing of NOD diabetes loci:

The appropriate PCR pnmer paIrS for

polymorphic microsatellite markers of diabetic susceptible alleles of NOD mice were
based on the report of Serreze et al (370) and the Mouse Genome Database in Jackson
Laboratory. Those primers were purchased from Research Genetics and listed in Table
5-1. Mouse tail DNA was extracted from transgenic NOD offspring and control FVB
and NOD mice with Qiagen DNAeasy Kit (Qiagen, Valencia, CA) according to the
manufacturer instructional manual. PCR reaction was performed in a 20 /-ll volume
containing 1.5 /-ll sample DNA (about 20ng DNA), 200 /-lM dNTP, 0.2 /-lM of each
primer, 0.45 unit of Platinum Taq DNA polymerase, 16 mM (NH4)2S04, 67 mM TrisHCI, pH 8.8, 0.01% TWEEN-20, and appropriate concentrations of MgCb. MgCb
concentrations were varied between 1 and 5 mM based on different primer sets (Table
5-2). PCR reaction was carried out in an Eppendorf thermocycler equipped with a
heated hood. The reaction contained a first polymerase activation step at 95°C for 2 min,
followed with 32 cycles of amplification, and ended with an extenstion step at
7 min.

nOc for

Each amplification cycle consisted of 45 seconds of denaturing at 94°C, 45

seconds of annealing at 57°C and 1 min of extension at

nOc.

PCR products were

fractionated on 6% NuSieve (FMC) agarose/TAE and stained with 0.5 /-lg/ml ethidium
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bromide. Control PCR reactions of inbred FVB and NOD mouse DNA were exerted
every time and were fractioned in parallel to PCR products from other samples in order
for a clear-cut discrimination of NOD diabetic allele from FVB normal allele. The PCR
Mg2+ concentration and approximate size of PCR products from FVB and NOD strains
for each set of micro satellite markers were summarized in Table 5-2.

peR typing of transgenes: To determine the presence of trans genes, mouse tail

DNA was extracted with Qiagen DNAeasy kit (Qiagen, Valencia, CA) according to the
manufacturer instructional manual. PCR reaction was performed in a 20 fl.l volume
containing 1.5 fl.l sample DNA (about 20 ng DNA), 200 fl.M dNTP, I fl.M of each
primer, 0.8 unit of Platinum Taq DNA polymerase, 2 mM MgCh and 10mM Tris 1x
PCR buffer (Invitrogen, Carlsbad, CA). PCR reaction was carried out in an Eppendorf
thermocycler equipped with a heated hood. The reaction contained a first polymerase
activation step at 95°C for 2 min, followed with 35 cycles of amplification, and ended
with an extension step at

nOc for 7 min.

Each amplification cycle consisted of 1 min

of denaturing at 94°C, 1 min of annealing at 57°C and 1 min of extension at

n°c. PCR

products were fractionated on 0.9% agarose gel in TAE electrophoresis buffer and
stained with 0.5 fl.g/ml ethidium bromide. The sequences for each set of primers for
each transgene were as follows: MnSOD (forward 5'-GGATCCTGAGAACTTCAG-3',
reverse

5'-TTCTGCCTGGAGCCCAGATAC-3');

AATATCGTGGGTGACCTCAA-3',
MT

(forward

reverse

Catalase

(forward

5' -

5'-GGATCCTGAGAACTTCAG-3');

5'-AATCGGTTGTGGACTGAGGA-3',

reverse

5'-

CCTGA TAAGATCACTGAGGA-3 '). In addition to the primers for transgene, another

n

set

of

primers

(forward

5'-CTGGTGATGGCTTCCTTG-3',

reverse

5'-

CTCAATGTTGAGCAGGAA-3') was included in every PCR reaction in order to
monitor the quality of DNA sample and PCR reaction. This pair of primers was used to
identify heme oxygenase which is ubiquitously expressed in all strains of our mice. At
each time control PCR reactions for trans gene positive and negative DNA were also
performed.

Immunohistochemistry for insulin, MT, Catalase, MnSOD and cleaved-caspase

3: Transgenic or control mouse pancreas was fixed in 10% formaldehyde in 0.1 M
phosphate buffer (pH 7.2), dehydrated in an ascending graded series of ethanol and
subsequently infiltrated with paraffin. Serial sections were cut at 5flm, mounted on
polylysine coated slides and then rehydrated in a descending graded series of ethanol.
Slides were treated with 3% hydrogen peroxide followed by an additional 10 min
incubation with Power Block

(Biogenex).

Sections were treated with primary

antibody (rabbit anti-guinea pig insulin antibody diluted 1 to 100 or rabbit anti-catalase,
mouse anti-horse MT and sheep anti-human SOD antibodies at a 1:50 dilution or rabbit
anti-cleaved-caspase-3 at 1:500). Primary antibody incubations were 90 min at 37°C.
After 4 washes in phosphate buffered saline slides were incubated with the appropriate
either fluorescence-labeled second antibody or biotin-labeled second antibody followed
by peroxidase labeled streptavidin and developed with 3-amino-ethylcarbazone (AEC)
as chromagen.

Slides without primary antibody treatment were used as negative

control. To examine the cellular localization of MnSOD and catalase expression, the
immunostained MnSOD and catalase transgenic islets were visualized with a Zeiss 510
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LCSM laser scanning confocal microscope using FITC/rhodamine barrier filters with
excitation settings of 543 and 488 nm, respectively. Lasar scanning confocal sections
was obtained with 0.3-!lm steps for at least one cell layer within the islet. Maximum
intensity z-axis projections for three sections (1 !lm thick) was constructed.

Islet isolation: The isolation procedure was based on a modification of the method
of Gotoh et al (371). Mice were anesthetized with avertin at the dose of 6 mg/g body
weight via intraperitoneal injection. The pancreas was inflated with 3 ml of 1.55 mg/ml
collagenase Type V, and carefully removed from the mouse body and incubated at 37°C
for 20 min. Digestion was stopped by adding cold HBSS followed by vigorous shaking
and 3 washes in 50 ml cold HBSS and passage through a 200 !lm mesh. The final
pancreas pellet was resuspended in 10 ml Histopaque 1077, overlaid with 10 ml of
HBSS and centrifuged at 700x g for 20 min at 10°e. Most of the gradient, excluding
the pellet was collected and washed twice with cold HBSS. Islets were then handpicked
and maintained in islet culture medium at 37°C and 5 % CO 2 plus humid air. Islets were
normally used the day after isolation.

For experiments requiring extended culture,

medium was changed every two days.

Assays for insulin secretion, insulin content and DNA content. Glucose
stimulated islet insulin secretion was measured by static assay on 96-well tissue-culture
microplates. For each well 6-10 islets were hand picked into modified KRB buffer
containing 3 mM glucose at 37°C.

After two washes in 3 mM glucose modified KRB

74

solution, the islets were incubated for consecutive 30 min incubations in 200 /-11 of 3 and
20 mM glucose modified KRB solution. The supernatant was removed carefully for the
measurement of released insulin. To determine islet insulin content, islets were
sonicated in 150 /-11 10mM Tris HCl, ImM EDTA, Img/ml RIA grade BSA, pH 7.0 for
30 seconds. Fifty /-11 of the solution was used to extract islet insulin with 100 /-11 acid
ethanol at 4 °c overnight. The remainder of the sonicate was digested with an equal
volume of 200 /-1g/ml proteinase K in 100 mM Tris HCl, pH 8.5, 5 mM EDTA, 0.2 %
SDS at 55°C for 2 hours and used for islet DNA quantification with picogreen kit from
Molecular Probes (Eugene, OR). Insulin was measured with the coated tube RIA kit
from Diagnostic Products (Los Angeles, CA) and rat insulin standards.

Measurement of glothothine peroxidase activity in isolated islets: Islet Gpx
activity was measured by Glutathone peroxidase assay kit (Cayman Chemical
Company, Ann Arbor, MI). The kit measures Gpx activity indirectly by a coupled
reaction with glutathione reductase. Oxidized glutathione, produced upon reduction of
hydroperoxide by Gpx, is recycled to its reduced state by glutathione reductase and
NADPH. The oxidation of NADPH to NADP+ is accompanied by a decrease in
absorbance at 340 nm. Under conditions in which the Gpx activity is rate limiting, the
rate of decrease in the A340 is directly proportional to the Gpx activity in the
sample(372). 100 islets were sonicated in 250 /-11 of prechilled assay buffer (50mM
Tris-cacodylic acid, pH 8.2, ImM diethylenetriamineeprentaacetic acid) for 1 min on
ice. After solubilization for 30 min on ice, the sonicate was centrifuged at 20,000x g for
30 min. The supernatant was used to determine islet Gpx activity performed in a 96-
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well plate. In each well 20 /-11 of the supernatant was mixed with 100 /-11 of assay buffer
and 50 /-11 of co-substrate mixture, followed by a quick addition of 20 /-11 cumene
hydroperoxide. After carefully shaking the plate for a few seconds, the absorbance was
read in a microplate reader at the wavelength of 340 nm for 10 min at a 1 min interval.
The absorbance increasing rate of each well was calculated. Gpx activity was
determined from a standard curve obtained with bovine erythrocyte Gpx (Sigma).
Values were expressed per mg of islet protein in the sonicate, determined with the
Pierce BCA protein assay.

In vivo glucose tolerance test: Prior to the test, sex- and age-matched mice were
fasted overnight (about 16 hours). On the second day, mice were injected i.p. with a
sterile 10% glucose solution at a dose of 1 glkg body weight. Tail blood glucose of each
mouse was measured by a glucometer (OneTouch Ultra, Life Scan) at the times 0, 5, 15,
30,60, 120 min after glucose administration.

In vivo STZ treatment. For MT transgene study, a total of 10 MTNOD mice and
10 control NOD mice received a single intraperitoneal injection of freshly dissolved
STZ in 0.1 molll sodium citrate (pH 4.5) at a dose of 180 mglkg body weight. Mice
were sex-matched at the age between 10 and 17 weeks. The tail blood glucose levels
were monitored daily up for six days after STZ treatment by a glucometer (OneTouch
Ultra, Life Scan, Milpitas, CA).
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Cyclophosphamide administration and diabetes monitoring: Age and sex matched
transgenic and nontransgenic NOD mice received two doses of intraperitoneal injection
of 200mg/kg body weight of cyclophosphamide. The first and second injections were
two weeks apart. The mouse tail blood glucose level was monitored using a glucose
meter (OneTouch Ultra, Life Scan) every other day after first injection of CYP. Mouse
was considered diabetic after two consecutive readings of blood glucose over 200 mg/dl.
The onset of diabetes was dated from the first of these two sequential measurements.
Some mice were sacrificed after 8 days of CYP injection. Pancreas was removed for
pancreatic insulin measurement, histology and immunohistochemistry study.

H&E staining and insulitis score: Transgenic or control mouse pancreas was fixed
in 10% formaldehyde in 0.1 M phosphate buffer (pH 7.2), dehydrated in an ascending
graded series of ethanol and subsequently infiltrated with paraffin. Serial sections were
cut at 5flm, mounted on polylysine coated slides. Slides were stained with hematoxylin
and eosin with a standard protocol. The severity of insulitis was scored blindly in H&E
sections. Insulitis category includes no-insulitis, peri-insulitis, intra-insulitis and atrophy
islets. Results were expressed as mean islet percentages for each insulitis category in an
individual mouse. In each group data were collected from at least three mice and each
mouse was examined with 3 or 4 slides.

Islet IB-l expression after cytokine treatment: The messenger RNA level of iNOS
ill

cultured islets was measured by real-time quantitative RT-PCR. Eighty to one
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hundred overnight-cultured islets were treated without or with cytokines
recombinant

interleukin-1~

(mouse

5 U/ml plus interferon-y 100 U/ml) in 300 /-tl culture

medium for six hours in 1.5 ml microtubes. After treatment islets were rinsed with fresh
HBSS solution twice and islet total RNA was extracted with an RNA preparation kit
from Stratagene (Absolutely RNA Microprep Kit, Stratagene, La lalla, CA) according
to the manufacturer instructional manual. The RNA sample was treated with DNase to
remove all traces of genomic DNA contamination and its concentration was determined
by Ribogreen RNA quantification kit (Molecular Probes, Eugene, OR). Fifty ng total
islet RNA was reverse-transcribed to cDNA with a StrataScript reverse transcriptase
(Stratagene) in the presence of oligo dT based on the manufacturer provided procedure.
Real time quantitative PCR was prepared using Brilliant™ plus Two-Step Quantitative
RT-PCR Core Reagent kit

(Stratagene) and executed using Mx4000TM real-time

multiplex quantitative PCR system (Stratagene). The cDNA sequences for murine

~

actin and iNOS were obtained from GenBank, and the primer and probe sequences were
designed using Primer3 software (Steve Rozen and Helen 1. Skaletsky (2000) Primer3
on the WWW for general users and for biologist programmers. In: Krawetz S, Misener
S

(eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology.

Humana Press, Totowa, Nl, pp 365-386). To avoid amplification of genomic DNA, the
primer-probe sets were designed to span exon-exon boundaries.

The probes were

labeled with a fluorescent reporter 6-carboxyfluorescin (F AM) at the 5' end and a
quencher, 6-carboxytetramethylrhodamine (T AMRA) at the 3' end. The sequences for
the primer-probe sets for each gene were as follows: IB-1
CTGCCACTGTCTATGACAAC-3',

reverse
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(forward

5'-

5'-TCCTCATACTCCTCACCAAT-3',

probe 5'-6FAM-CCTCCTCGCCCTACGAGTCA-TAMRA-3');
ATGGCTGGGGTGTTGAAGGT-3',

~-actin

reverse

TACAATGAGCTGCGTGTGGC-TAMRA-3',

(forward 5'5'6FAM5'-

probe

CACCCTGTGCTGCTCACCGAGGC-3'). PCR amplifications were performed
total volume of 25 Ill, containing 1 III of cDNA sample (transcribed from

~50

III

a

ng total

islet RNA), 900 11M of each primer, 250 11M of the corresponding probe, 2.0 III of
GAUC mix (200 11M each of dATP, dCTP and dGTP, but 400 11M of dUTP), 0.01 U/lll
Uracil-DNA-N-glycosylase (UNG), 0.05 U/lll of SureStart Taq DNA polymerase, 1 x
core PCR buffer, 5.5mM MgCh. For each reaction, UNG reaction was processed at
50°C for 2 min followed a polymerase activation step at 95°C for 10 min, then
amplification was executed by alternating between 95°C for 15 s and 60°C for 60 s for
40 cycles. The sample !B-1 and

~-action

mRNA levels were calculated respectively

from standard curves of !B-1(0.01-800 ng total RNA) and

~-actin(0.01-800

ng total

RNA) using FVB control islets. Data were expressed as folds of !B-1 expression over
~-actin

expression.

Western blot: Fifty to one hundred freshly isolated islets from transgenic and control
mice were lysed in 30 to 40 III ice-cold lysis buffer (containing 20mM Tris, pH 7.5,
150mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 2.5mM sodium
pyrophosphate, 1mM

~-glycerophosphate,

ImM Na3V04, ImM OTT, Illglmlleupeptin,

and ImM PMSF). After determination of protein concentration by Pierce BeA kit, 5 to

10

~g

lysate proteins are separated by SDS-P AGE (discontinuous 20% mini-gel, Bio-

Rad) for 2 hours at 120 volts. The separated proteins were transferred onto PVDF
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membrane (Amersham) for 1.5 to 2 hours at 30 volts. After transfer, the membrane was
blocked in 5% dry milk in TBS containing 0.1 % Tween 20 for 1 hour. The membrane
was then incubated with various mouse or rabbit antisera directed against phosphor-Akt
(1: 1000 dilution), Akt (1: 1000 dilution), phosphor-Foxo 1 (1: 1000 dilution), Foxo 1

(1: 1000 dilution), PDX-1 (1 :7000 dilution), cleaved-caspase 3(1: 1000), total caspase 3
(1: 1000) and

~-actin

(1 :4000 dilution) overnight at 4°C. Following extensive washing,

membrane was further incubated with HRP labeled secondary anti-mouse or anti-rabbit
antibody (1 :2000 dilution) for 1 hour at room temperature. Immune complexes were
identified using ECL plus kit (Amersham) and visualized by Molecular dynamics Storm
system or film exposure.

Cell viability assay by Alamar Blue: The Alamar Blue assay, which incorporates a
redox indicator that changes color and fluorescence in response to cell metabolic
activity, is a commonly used method to assess cell viability and/or proliferation of
mammalian cells (373) and micro-organisms (374). In our studies, 15 overnightcultured FVB control islets or transgenic islets were hand picked into 200 )11 fresh
culture medium (no phenol red) containing 1:20 diluted Alamar Blue in a 96-well plate.
Islets were cultured for 4 hr and the Alamar Blue fluorescence was measured on a
fluorescent microplate reader (Tecan, Durham, NC) at the excitation wavelength of 535
nm and the emission wavelength of 595 nm. This measurement provided an absorbance
value indicating the pretreatment metabolic activity and was used to normalize the posttreatment metabolic activity. After three washes with fresh culture medium, islets were
cultured in 200 )11 culture medium containing various agents, including H20 2 and STZ,
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at various concentrations for varying time. In the end of treatment, fifty ~l culture
medium was replaced with 50

~l

fresh culture medium containing 1:5 diluted Alamar

Blue, for a final dilution of 1:20. The color was developed for another 4 hr and the
fluorescence was measured again. A fluorescent value from the "blank well", which
contained no islets but exactly followed the above procedure with highest level of ROS
treatment, was deducted from all other fluorescent values. Islet cell viability was
calculated as the ratio of fluorescence after treatment to the fluorescence before
treatment. The untreated islet cell viability was arbitrarily set as 100%.

Islet cell viability after cytokine treatment or cytokine combined with different
drugs. Islet cell viability was indicated by islet cell metabolic activity that was
measured with Alamar Blue, as described above. In detail, fifteen overnight-cultured
islets were hand picked into 200

~l

fresh culture medium (no phenol red) containing

1:20 diluted Alamar Blue in a 96-well microplate. A pre-treatment 4-hr metabolic
activity of the islets was measured for normalizing the post-treatment islet metabolic
activity.

After three washes of fresh culture medium (no phenol red), islets were

cultured for six days in 200

~l

culture medium (no phenol red) supplemented with or

without varying concentrations of cytokines (mouse recombinant interleukin-l ~ plus
interferon-y). Every other day 100
culture medium

~l

culture medium was replaced with 100

~l

fresh

(no phenol red) containing cytokines, thereby no change of final

cytokine levels. In the end of treatment, 50

~l

culture medium was replaced with 50

~l

fresh culture medium containing 1:5 diluted Alamar Blue, for a final dilution of 1:20.
The color was developed for another 4 hr and the fluorescence was measured again. A
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fluorescent value from the "blank well", which contained no islets but exactly followed
the above procedure with highest level of cytokine treatment, was deducted from all
other fluorescent values. Islet cell viability was calculated as the ratio of fluorescence
after treatment to the fluorescence before treatment. The untreated islet cell viability
was arbitrarily set as 100%.

Measurement of ROS production after cytokines treatment:

Control or transgenic

islets were loaded with 5 IlM CM-H2DCFDA for 30 min followed by three washes of
fresh culture medium. These loaded DCF islets were exposured to cytokines (mouse
recombinant interleukin-l ~ plus interferon-y) for 16 hrs. The fluorescence of each islet
was activated at an excitation wavelength of 485 nm and recorded at an emission
wavelength of 530 nm. ROS was monitored from randomly sampled individual islets
using a fluorescence microscope equipped with a digital camera. Images were analyzed
with ImagePro software (Media Cybernetics, Silver Spring, MD). More than 100 islets
from at least three separate islet isolations were studied for each group. The results were
expressed as the mean fluorescence intensity.

Data analysis: Data are presented as the mean ± standard error. Statistical analysis was
performed by one-way or two-way ANOVA and Dunnet's post hoc (2-tailed) test.

Computations were carried using statistical programs from SPSS (version 10.0) and
Sigmastat (version 2.03). The cumulative incidence of diabetes was calculated for each
group and the significant difference was tested by Kaplan-Meier survival test using
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SPSS program (version 10.0). Two-way ANOVA and Dunnet's post hoc (2-tailed) test
were used to test the difference between transgenic and control NOD mice before and
after CYP treatment.
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RESULTS

Production of transgenic NOD mice con genic for MT, catalase, or MnSOD
transgene:
In our lab, we already generated MT, catalase and MnSOD transgenic FVB mIce.
Therefore using speed congenic method (Fig. 2-1), MT, catalase or MnSOD transgenic
FVB mice were backcrossed to NOD mice at least five times. Starting from the third
generation, trans gene positive offspring were selected for peR genotyping of 19
diabetic susceptible alleles. These new congenic mice which were found homozygous
for all 19 diabetic susceptible alleles (Fig. 2-2) were used as founders to breed with
NOD mice one more time. The offspring were inter-crossed to maintain the line and
produce transgenic and nontransgenic littermates used in this study.

In order to rule out the possibility of ectopically expressing these trans genes in tissues
other than islets, western blotting for islets, brain, heart, lung, muscle, liver, intestine,
kidney, bone marrow, thymus and spleen from control and transgenic NOD mice was
performed. The results (Fig. 2-3) demonstrate that high levels of transgenic catalase
trans genes are specifically expressed in transgenic islets.

Although catalase was also

expressed in other tissues such as lung, liver, intestine, kidney, thymus and spleen, the
levels of expression in transgenic mice were indistinguishable from control mice.
Moreover, the size of transgenic catalase was different from the endogenous catalase.
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Immunohistochemical staining of catalase, MT and MnSOD shown in Fig. 2-4 further
demonstrates that these trans genes were specifically overexpressed in pancreatic beta
cells. In addition, immunoreaction for MnSOD by confocal laser scanning (E, inset) is
granular,

indicating

typical

mitochondrion-like

staining

pattern.

In

contrast,

immunoreactions for catalase (E2, inset) and MT (El, inset) were evenly distributed in
the cytoplasm, indicating unlike MnSOD, they were mainly overexpressed in cytoplasm.
In addition, both transgenic and control NOD mice had similar insulin staining.

To determine whether the antioxidant transgenes enhanced pancreatic beta cell ROS
scavenging ability in the NOD background, transgenic MTNOD and control NOD mice
were injected with STZ (180 mg/kg body weight), which is well known to destroy
pancreatic beta cells through ROS production, which induces experimental diabetes.
After STZ treatment, the blood level of both transgenic and control NOD mice were
monitored every day. Data in Fig. 2-5 demonstrated that MT could significantly delay
STZ induced diabetes onset, suggesting MT would have the same antioxidant protective
effect against toxins on the NOD background as it did on the FVB background (375).

The evaluation of islet function and structure in transgenic NOD mice: Since
several trans genes have produced unintended beta cell dysfunction, we also
characterized these transgenic islets with respect to pancreatic islet morphology and
insulin content, isolated islet insulin content, DNA content, protein content and glucose
stimulated insulin secretion. The data showed that both transgenic and nontransgenic
NOD mice at less than 42 days of age contained similar pancreatic insulin content and
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also had similar insulin content, DNA levels and protein levels in isolated islets (Table
2-1). In addition, these transgenic islets have similar glutathione peroxidase activity as
control NOD islets (Fig. 2-6).

Insulitis is a special morphological characteristic of NOD mice. Figure 7 showed that
our transgenic NOD mice also generated the same extent of insulitis as control NOD
mice. In addition both transgenic and control NOD mice had similar insulin staining
(Fig. 2-7). These results demonstrated the MT, or catalase overexpression was not
harmful to the beta cell.

The acceleration of NOD diabetes onset by cytoplasmic antioxidants MT or
catalase but not mitochondrial MnSOD:
Using these MTNOD, CatNOD and SODNOD mice we tested the potential effect of
beta cell antioxidant transgenes on NOD diabetes. Transgenic NOD and control NOD
mice were injected with CYP twice at a dose of 200 mg/kg. After the first injection
diabetes onset and incidence were determined by the occurrence of hyperglycemia. To
our great surprise, the MT and catalase trans genes remarkably speeded up NOD
diabetes (Fig. 2-8), instead of delaying the onset of diabetes as we had hypothesized.
However in SODNOD mice, diabetes developed at a similar time as in control NOD
mice after injection of CYP. This accelerated diabetes onset was confirmed by
measurement of pancreatic insulin levels in transgenic MT and control NOD mice
before and after CYP injection.
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As shown in Fig. 2-9, the pancreatic insulin content in MTNOD and control NOD mice
was similar before CYP injection. However, 8 days after CYP injection the pancreatic
insulin level in MTNOD and CatNOD mice was only 50% of their original value before
CYP injection; whereas the control NOD mice preserved almost 80% of their original
insulin. This suggested that more beta cells were destroyed in MTNOD mice than in
NOD mice after CYP injection.

This result was unexpected, and completely opposite to our original hypothesis that
ROS scavengers would be helpful to prevent type 1 diabetes. Therefore, we measured
spontaneous diabetes onset in both transgenic and nontransgenic NOD mice. The data
(Fig. 2-10) showed that all male MTNOD and CatNOD mice developed diabetes more
quickly than control male NOD mice (p<0.05, by Kaplan-Meier survival analysis and
Mantel-Cox Log-rank test), which indicated that overexpression of cytoplasmic
antioxidants MT and catalase accelerated NOD spontaneous diabetes onset.

MT and catalase overexpression accelerates beta cell apoptosis after CYP injection:

To determine what kind of cell death MTNOD and CatNOD islets undergo,
immunohistochemistry was performed to measure cleaved caspase-3 staining in
pancreatic islets from both transgenic and control NOD mice before and after CYP
injection. As shown in Fig. 2-11, six days after CYP injection, both MTNOD islets
contain higher cleaved caspase-3 staining than control islets, which demonstrated that
MTNOD and CatNOD islets undergo apoptosis more quickly than control NOD islets
after CYP injection.
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Analysis of IB-l expreSSIOn as shown in Fig. 2-13, another important anti-apoptic
protein in islets (376-378), revealed that IB-l mRNA expression by RT-PCR was
significantly reduced to 50% of original level in MTNOD and CatNOD islets after CYP
injection. In addition, insulitis score (Fig2-13 ) either before or after CYP injection was
similar in both transgenic and control NOD mice except that the percentage of atrophic
islets was higher in transgenic mice ( about 30%) than in control NOD mice ( 10%).

In vitro susceptibility of MT and catalase islets to cytokine toxicity:
It is well established that inflammatory cytokines suppress pancreatic beta cell insulin

secretion and lead to cell death through apoptosis and necrosis (379;380). In this study,
both cell viability by Alamar Blue and cleaved caspase-3 expression by western blot
were assessed in cultured control NOD and transgenic islets after exposure to cytokines.
After 24 hrs cytokine treatment, MT decreased islet cell viability dose dependendently
( Fig. 2-14) and catalase also was found to inhibit islet survival at 0.5X concentration of
cytokines (Fig. 2-15 ) . Cleaved caspase-3 expression in MT islets (Fig. 2-16) was
higher than control islets at both 12 and 24 hrs after cytokine treatment, in spite of the
fact that both catalase and MT could dramatically decrease cytokine induced ROS
production (Fig 2-24). Furthermore, IB-I expression was also decreased in both MT and
CatNOD islets treated with cytokines for 48 hrs( Fig. 2-I7).These data suggest that MT
and catalase sensitize islet to cytokine toxicity.

Reduction in activity of the PI3K1Akt pathway in MTNOD and CatNOD islets
after CYP injection: The above results demonstrated that overexpression of
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cytoplasmic antioxidants accelerated NOD type 1 diabetes onset, instead of protecting
from diabetes onset. Since these results were obtained with two independent
antioxidants: catalase and MT, we hypothesized that a low level of ROS was essential
for maintaining or stimulating some beta cell survival pathway during diabetes stress
and overexpression of

antioxidant could suppress these protective pathways by

scavenging ROS. To test this hypothesis, we measured the activity of PI3K1Akt
pathway, one of the important protective pathways in beta cell. After 4 or 7 days
beyond CYP injection, p-Akt and PDX-I expression were significantly decreased in
MTNOD and CatNOD islets compared with control NOD islets (Fig. 2-18, 2-20 and 221). Since PDX-l expression is inhibited by transcription factor Foxol, corepressor of
PDX-l, Foxo 1 could be phosphorylated by p-Akt and retained in the cytoplasm (by
nuclear exclusion) which would finally increase PDX-l expression. Therefore we also
measured p-Foxol expression. Results (Fig. 2-19) show decreased p-Foxol expression
in MTNOD islets but not in control NOD islets after CYP injection. These results
suggest that catalase and MT overexpression reduced PI3K1Akt pathway activity after
CYP injection.

In vitro susceptibility effect of MT and catalase on islets to cytokine toxicity is due
to lower PI3K1Akt activity: Data from Fig. 2-22 suggested that overexpression of

catalase and MT sensitized islet to cytokine toxicity and the PI3K inhibitor wortmannin
could normalize NOD islet cell death to similar level as seen in MTNOD islets.
Consistent with in vivo results p-Akt, p-Foxol and PDX-I expression ( Fig. 2-23) were
significantly decreased in MTNOD islets after 6 hrs cytokines treatment. So, the in vitro
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susceptibility effect of MT and catalase to cytokine toxicity also might be due to lower
PI3K1Akt activity.

Lower ROS may produce higher PTP activity in MTNOD islets after cytokine
treatment:
The activation of protein tyrosine phosphatase has been found to be reversibly inhibited
by ROS in several protein tyrosine kinase pathways (381-383). Firstly, we measured
the ROS production induced by cytokines in transgenic and control islet using the DCF
method. As shown in Fig. 2-24 both MT and catalase significantly reduced ROS
production after 16 hrs cytokine treatment. Fig. 2-25 had shown that the PTP inhibitor,
vanadate, could reverse the sensitization effect of MT to cytokine toxicity, which
suggested that elevated cytosolic antioxidants may result in higher PTP activity in beta
cells by protecting PTPs from ROS, thereby causing decreased beta-cell activity of the
PI3K1Akt survival pathway.
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DISCUSSION

In present study, overexpression of cytoplasmic antioxidants sensitize to both CYP
induced and spontaneous type 1 diabetes. Caspase-3 expression showed that the rapid
induction of diabetes was due to greatly increased level of apoptosis in transgenic NOD
islets. This increased susceptibility is unlikely to be due to the direct damaging effect of
the transgenes since the transgenic NOD mice at young age had similar pancreatic
insulin level, beta cell function and structure as control NOD mice. Moreover, these
antioxidant transgenes make the beta cell more resistant to STZ toxicity. Other potential
artifacts that could explain this result also have been ruled out: In vitro studies showed
that MT did not sensitize islets to CYP toxicity, in fact, it provided significant
protection (data not shown), which indicates that our results were not due to direct
sensitization of beta cells to CYP toxicity by antioxidant transgenes. Western blot data
from Fig 3 also rules out the possibility that ectopic overexpression of antioxidant
transgenes in other tissues, might alter the immune response in transgenic NOD mice.
Likewise, increasing susceptibility in transgenic NOD mice cannot be attributed to other
antioxidants compensatory changes caused by MT or catalase overexpression, because
we found no difference in activity of glutathione peroxidase between transgenic and
control NOD mice (Fig 6 ). Finally, this sensitization effect occurs on two different
transgenic antioxidant mice, which rules out the possible damaging effect due to
Therefore, our current data suggest

transgene insertion to genomIc DNA.

overexpression of cytoplasmic antioxidant proteins in pancreatic beta cells increases
susceptibility to NOD mice.
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This finding runs complete contrary to what has been proposed for oxidative stress and
type 1 diabetes. It is generally believed that oxidative stress contributes to autoimmune
mediated demise of beta cells (384;385), however, there is very limited data for this
proposal which specifically targets the beta cell. For in vivo studies, systemic treatment
with antioxidants is most often performed. However, the major ambiguity in those in
vivo studies is the site of protection, since the protection of delaying diabetes onset with
systemic antioxidant treatment could be produced at the immune system rather than
directly at pancreatic beta cells(386). The studies where antioxidant treatment has been
directly targeted to beta cells are not only limited but the results are also controversial.
Adenoviral expression of MnSOD was partially effective against cytokines in isolated
primary islets(387). However, beta cell specific overexpression of the secreted form of
SOD had no effect on NOD diabetes(388). Thioredoxin overexpression in beta cell
delays NOD diabetes onset(389), but thioredoxin has an additional very potent antiapoptotic effect, which may contribute to this significant benefit. Therefore, it is still not
clear what roles ROS play in type 1 diabetes. In vitro most of beta cell tumor lines
studies provide pretty consistent results that antioxidants provide protection from ROS
and cytokine induced toxicity(390-394). But the relevance of these antioxidant
protective results from beta cell tumor lines is still uncertain due to the difference in cell
survival between primary beta cells and tumor cell lines. It has been noted that tumor
cell lines have either abnormal amplification and overexpression of survival signal such
as constitutive Akt activation or survival pathways which often can not be controlled by
normal regulation(395-397).
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Furthermore, it has been shown that treatment of isolated islets with antioxidants does
not always reduce cytokine toxicity(398;399). The explanation for the difference
between our data and data from in vitro beta cell tumor lines could be that ROS have
dual functions in the pancreatic beta cell during immune attack, one is ROS acting as
signal involving survival pathway regulation, and the other is a damage effect. In
primary beta cells, it might be very important for delaying beta cell destruction that
ROS act as protective signal activating beta cell protective response. However, in beta
cell tumor lines, the ability of their survival is already highly amplified, which make the
role of ROS as survival signal much less important. In beta cell tumor lines,
overexpression of antioxidants mainly provides protection from ROS damage effect.
Our result that cytoplasmic antioxidants overexpression in the beta cell accelerated
NOD type 1 diabetes implies that cytoplasmic ROS have an important role in
maintaining beta cell survival in the presence of immune attack.

It is not new that ROS act as signal molecular, and our results also are not without

precedents in other cell types. For example, the proapoptotic effects of antioxidants
such as catalase have been reported (400). Low dosage of ROS such as NO, has
antiapoptotic effects on several cell systems(401-403). Recently low dosage NO has
been found to provide protection from apoptosis in pancreatic beta cells through
activating the PI3K1Akt survival pathway(404;405).

Although ROS are involved in regulating many signaling pathways, the signaling
molecules targeted by ROS have remained largely unexplored. Lots of evidence
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suggests that ROS regulation could occur at multiple levels in the signaling pathways
from receptor to nucleus. However, recently protein tyrosine phosphatase has received
more attention as an ROS targeted signaling molecule. ROS can reversibly inactivate
PTPs by the direct oxidation of cysteine in the active site of these enzymes (406). It has
been reported H202 treatment could inhibit PTPs in vitro (407) as well as in several
cell lines (408-410). Antioxidants such as N-acetylcysteine (NAC) inhibits H202induced phosphatase inactivation in glia cell lysate(20 1). Our cell viability result that
the PTP inhibitor, vanadate, could rescue MTNOD islet from cytokine toxicity indicates
that the antioxidant transgenic islets might have higher PTP activity due to low ROS
compared with control NOD islets.

It is well known that fully active PTPs can efficiently remove phosphate from tyrosine

residues and destroy binding sites for other signaling molecules such as PI3K.
Therefore, inhibition of PTP by ROS could enhance tyrosine receptor induced
downstream cellular signaling. Among these tyrosine receptor induced cellular
signaling pathways, the Irs-2 branch of insulinlIGF signaling has recently been found to
playa key role in beta cell survival and function (287;288). In mice, both Irs-l knock
out and Irs-2 knock out are markedly insulin resistant, however, only Irs-2 knock out
mice fail to sustain compensatory insulin secretion due to decreased beta cell mass
compared with wild-type and Irs-l knock out mice, and they eventually developed
diabetes. However, the diabetes due to Irs-2 knock out could be reversed by crossing
with PTPIB knock out mice(296), indicating PTP might be a critical regulator in IRS-2
branch of insulinlIGF signaling.
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The IRS-2 branch of insulinlIGF signaling promotes cell survival at least in part by
activating the PI3K and its downstream target Akt. It has been shown that Akt activity
is both necessary and critical for beta cell survival. Loss of Akt2 produces insulin
resistance and pancreatic beta cell failure and loss, which finally results in severe
diabetes(290). Increased expression of Aktl in pancreatic islets protects from STZ
induced diabetes and against free fatty acid induced beta cell apoptosis(291 ;292).
Activation of Akt by IGF protects islets from cytokine toxicity(293;294;322) and
improves human islet graft survival in diabetic NOD-SCID mice. Our in vivo CYP
injection and in vitro cytokine treatment studies have shown that activation of the
PI3KJAkt pathway in antioxidant transgenic NOD islets was reduced, consequently
phosphorylation of its downstream transcription factor FOXO-l also decreased and
expression of PDX-l was largely inhibited. Consistent with our results, recently Lei's
group found that overexpression of glutathione peroxidase induced development of
insulin resistance and obesity via reducing insulin-stimulated phosphorylation of the
insulin receptor and Akt(323). These data imply that normal intracellular ROS is
necessary for maintaining insulinlIGF mediated PI3KJAkt pathway activation and our
elevated cytosolic antioxidants may result in higher PTP activity in beta cells by
protecting PTPs from ROS, thereby causing decreased beta cell survival.

In our results, MnSOD overexpression, unlike catalase and MT, did not accelerate NOD
diabetes onset. It is known that MnSOD is different from MT and catalase with respect
to localization and which ROS species they inactivate. MT is present primarily in the
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cytoplasm. Catalase normally is found in peroxisomes, however when overexpressed in
transgenic animals a large amount of catalase is also present in cytoplasm (324).
Catalase specifically inactivates H202. MT scavenges H202 and many other ROS(279).
In contrast, MnSOD is expressed in the mitochondria ( Fig 4) and inactivates
superoxide and produces H202. It has been shown that cytokines could produce ROS
through mitochondria or cytoplasm (325). It is interesting and important to determine
whether the different ability to accelerate diabetes is due to localization of the
antioxidant or the species of ROS that is inactivated. To answer this question, our lab
plan to overexpress another antioxidant, SOD 1, which is cytoplasmic and only
inactivates superoxide like MnSOD.

Overall, our results provide in vivo evidence that ROS play an important role in beta
cell survival in type 1 diabetes, arguing against the current notion of the beneficial
effects of antioxidant enzymes on type 1 diabetes. This concept should be reconsidered
or modified to avoiding diminishing cytoplasm ROS in beta cell to the point where
survival is impaired.
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LIMITATION FOR THIS STUDY

Some limitations in this study need to be pointed out. The major limitation to our results
is that many the mice maintained in the animal facilities of the University of Louisville
by our lab currently are infected with mouse Parvovirus (MPV), which is one of the
most prevalent infectious pathogens in research institutions (326). MPV often replicates
in mitotically active tissues, such as gastrointestinal tract, lymphocytes, and tumors.
MPV has high resistance to temperature and harsh environmental conditions. In vivo,
MPV can remain infectious for a very long time after initial exposure, even in adult
mice (327). In general, MPV infection causes no clinical symptoms or diseases in
infected infant or adult mice, whether they are immunocompetent or severely
immunocomprised (SCID mice) (328). But MPV infections can alter immune function.
CD8+ and CD4+ cell function may be inhibited (329;330). Lymphocytes from the spleen
and popliteal lymph nodes showed inhibited function in one study (331). Therefore in
NOD mice MPV contamination theoretically could delay diabetes onset instead of
accelerating it. Although the rate of spontaneous diabetes onset in our NOD mice is
similar to what has been reported, we cannot be certain what impact MPV infection has
on transgenic NOD mice.

Our results need to be replicated in mice free of MPV

infection that are housed in pathogen-free facilities.

Also our conclusion that insulinlIGF / Akt pathway played an important role in
antioxidant trans gene sensitizing beta cell damage may not be complete. Other
mechanisms discussed in the introduction such as the MAPK pathway and the
transcription factor NFkappa B may be involved in our results.
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Fig 2-1. The breeding program for generation of consgenic NOD mice with beta
cell antioxidant overexpression. 3 lines congenic NOD mice, designated as MTNOD,
CatNOD and MnSODNOD, were produced with elevated beta cell specific expression
of metallothionein, catalase and MnSOD protein.
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Fig 2-2. peR-based genotyping of diabetic suseptible alleles in con genic NOD mice
with beta cell specific expression of MnSOD trans gene. Homozygosity of 19 NOD
diabetes loci (IDD) in the congenic NOD mlce was determined by peR usmg
polymorphic microsatellite markers linked with these Idds. This figure lS a
representative gel graph showing 19 Idd in two MnSOD congenic progenitors (S I, S2),
inbred NOD (N), and FVB (F) mice.
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Fig 2-3. Catalase transgenes overexpressed in pancreatic islet. Isolated islets, spleen,
thymus, bone marrow, kidney, intestine, liver, islet, muscle, lung, heart and brain from
both transgenic and control NOD mice were lysed for western blot analysis.
Representative blots showing catalase expression.
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Fig 2-4. Immunostaining for MT, Catalase and MnSOD in transgenic and control
NOD mice. Pancreaatic sections from both transgenic and control NOD were stained
with anti-MnSOD (A, B, green), anti·MT (Al,Bl , red) and anti-catalase (A2, B2,
brown) primary antibody. Immunostaining for MnSOD (green staining) in control (A)
and MnSOD transgenic islets (B, inset E) shows MnSOD overexpression that is
granular consistent with mitochondrial localization (Inset E). Similar results were
obtained for MT (AI, BI) and Catalase (A2 , B2), except that MT and catalase showed
cytoplasmic staining. MnSOD, MT and Catalase specifically expressed in transgenic
islets(B,B I ,B2), whereas almost no or very weak expression in control NOD islets(A,
A I, A2). Insulin staining was similar in control NOD(C, C 1, C2) and transgenic
islets(D,D 1,D2).
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Fig 2-5. MT overexpression reduced STZ induced diabetes on NOD background.
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body weight) of STZ via ip injection. Blood glucose levels were monitored daily for 6
days following the injection. Data shown are the mean value ± SE from 10 animals in
each group.

* indicates p<0.05, by two-way ANOV A.

error of the mean.
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Vertical bars show the standard

Islet DNA

Islet insulin

Pancreas insulin

(ng per islet)

(ng per islet)

(mU per gram wet tissue)

NOD

17.99 ± 1.65

112.08 ± 18.30

1609±176

MTNOD

17.17 ± 1.96

108.08 ± 35.93

1458 ± 178

CatNOD

15.54 ± 1.28

139.48 ± 9.07

1632 ± 332

Table 2-1. No alteration of isolated islet insulin content, DNA content and protein
content in transgenic mice at age of 30 days. Data are the means ± SE. No significant
differences were found among groups.
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Fig 2-7. Insulitis and pancreatic insulin level in transgenic and control NOD mice.
(A) Insulitis in NOD and MTNOD con genic mice at the age of 7-9 weeks. Sections
were stained with hematoxylin and eosin. Islet insulitis, the infiltration of lymphocytes,
was only seen in a small portion of pancreatic islets in both NOD and MTNOD mice.
Magnification X 200. (B) insulitis scores.

Th~

MTNOD mice developed similar severity

of insulitis as control NOD mice did at the age of 7-9 weeks.
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Fig 2-8. Cumulative diabetes incidence in control NOD, transgenic MTNOD,
CatNOD and MnSODNOD mice after CYP administration, Age and sex-matched
transgenic or nontransgenic NOD mice (age=6-9 weeks) were injected with CYP
(200mg/kg body weight via ip,) at days 0 and 14. Tail blood glucose was monitored
every other day. Onset of diabetes was defined as two consecutive measurements of
nonfasting blood glucose levels >200 mg/dl. Kaplan-Meier survival analysis and
Mantel-Cox Log-rank test revealed that MT and catalase significantly hastened NOD
diabetes onset (P<O.Ol), but MnSOD had no effect on NOD diabetes (P>0.05). Each
transgenic line was compared to simultaneously injected group of matched NOD mice.
It is notable that isolated MT transgenic islets were more resistant to CYP treatment

than nontransgenic islets (not show).
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Fig 2-10. Accelerated spontaneous diabetes onset in MTNOD and CatNOD male
mice. Non-fasting blood glucose was monitored every other week in transgenic and

control NOD mice. Onset of diabetes was defined when the first of two consecutive
measurement of non-fasting blood glucose level> 200 mg/dl was reached. KaplanMeier survival analysis and Mantel-Cox Log-rank test revealed that either MT or
catalase significantly hastened NOD diabetes onset (P<O.OI).
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Fig 2-12. The effect of MT and catalase transgenes on islet-brain protein-l (18-1)
expression in NOD mice before a nd after CYP administration. Both transgenic (MT
and catalase) and control NOD mice received a CYP injection at a dose of 200 mg/kg
via ip. Eight days later, mice were sacrificed and pancreatic islets were isolated. Islet
total RNA was extracted and real-time quanti tative RT-PCR was performed to
determine the expression of I B- 1. Results were normalized by islet beta-actin
expression. Antiox idant transgenes, either MT or catalase, caused a significant
reduction of islet IE-I expression in NOD mice after CYP treatment. The numbers of
each group was at least 4. Vertical bars stand for SE.

* P<0.05

between control NOD

and transgenic mice (MTNOD or CatNOD) by two-tail Student T-test.
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processed with standard histological procedure. The severity of insulitis was scored
blindly in H&E sections. Results were expressed as mean islet percentages for each
insulitis category in an individual mouse. In each group data were collected from at
least three mice and each mouse was examined with 3 or 4 slides. MT transgene
significantly enhanced pancreatic islet death (atrophy after CYP administration.
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cytokine mixture ( cyto, 1 X containing 1ng/ml IL-l~, 250 ng/ml interferon-y, 4 ng/ml

TNF-a) for 24 hrs. Islet cell viability was measured by the Alamar Blue assay. Data
were calculated from 3 to 5 independent experiments with duplicates or triplicates in
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* and ** indicate that the values are different from the corresponding

NOD control values (*, P<O.OI by two-way ANOVA). Vertical bars indicate standard
error of the mean.
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error of the mean.
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Fig 2-16. Increased caspase-3 expression in MTNOD islets after cytokine treatment.
Isolated islets from CatNOD

or NOD mice were exposed to the indicated

concentrations of cytokine mixture (cyto, 1X: 1 ngl ml IL-I b, 250 ng/ml interferon-g, 4
nglml TNF-a) for 12 or 24 hours. Islet protein extract was fractionated by SDS-PAGE

and analyzed by western blot using anti-cleaved caspase-3 antibody. B. Representative
image showing caspase-3 expression typical of three independent experiments.
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total RNA was extracted and real-time quantitative RT-PCR was performed to
determine the expression of IB-I. Results were normalized by islet beta-actin
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*

P<O.05 between control NOD and transgenic mice (MTNOD or CatNOD) by two-tail
Student T-test.
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Fig 2-18. Reduced Akt phosphorylation in MTNOD mice after CYP injection.
Transgenic MTNOD and control NOD mice were not (Day 0) or injected with CYP for
4 or 7 days. Pancreatic islets were isolated and lysed for western blot analysis. (A)
Representative blots showing Akt phosphorylation (activation). Each lane indicates an
independent islet preparation from one mouse. (B) Densitometric analysis. The activity
of Akt (Akt phosphorylation) was normalized by Akt expression. Data were collected
from 3 mice in the group of Day 0 and 5 mice in the group of CYP treatment for each
type of mice. Vertical bars indicate the standard error.

* P<0.05,

and b* * P<O.OI

between NOD and MTNOD 7 days after CYP injection, and a** P<O.OI in NOD mice
before and after CYP treatment by two-way ANOV A.
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Fig 2-19. Reduced Foxo phosphorylation in MTNOD mice after CYP injection.
Transgenic MTNOD and control NOD mice were not (Day 0) or injected with CYP for
4 days. Pancreatic islets were isolated and lysed for western blot analysis.
Representative blots showing phosphorylated Foxol expression. Each lane indicates an
independent islet preparation from one mouse.
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Fig 2-20. Reduced PDX-l expression in MTNOD mice after CYP injection.
Transgenic MTNOD and control NOD mice were not (Day 0) or injected with CYP for
4 or 7 days, Pancreatic islets were isolated and lysed for western blot analysis, (A)
Representative blots showing PDX-l expression, Each lane indicates an independent
islet preparation from one mouse, (8) Densitometric analysis. The PDX-I expression
was normalized by b-actin leveL Data were collected from 3 mice in the group of Day

°

and 5 mice in the group of CYP treatment for each type of mice, Vertical bars indicate
the standard erroL * P<0,05, and b* * P<O,OI between NOD and MTNOD 7 days after
CYP injection, and a** P<O,OI in NOD mice before and after CYP treatment by twoway ANOVA.
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treated with CYP for 4 days, and 10 f-lg islet protein extract was fractionated by SDSPAGE and analyzed by western blot using specific antibodies. Each lane indicates an
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not MTNOD islets. MTNOD and NOD islets were cultured in medium containing the
indicated concentrations of cytokines (1 ng/ml IL-l b, 250 ng/mt interferon-g, 4 ng/ml
TNF-a) in the absence or presence of 1 mM wartmanin for 24 hours. Islet cell viability
was measured by Alamar blue assay. Results come from 3 independent experiments
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* P<O.OI

for the indicated group vs.

control, and # P<0.05 for the indicated group vs. corresponding group treated with
cytokines (two-way ANOVA). Vertical bars indicate the SE.
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islet protein extract was fracti onated by SDS-PAGE and analyzed by

western blot using specific antibodies. Each lane indicates an independent islet sample.
Results are typical of two independent experiments.
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Fig 2-24. Reduced ROS production in MTNOD and CatNOD islets following
treatment with cytokines. Isolated islets were preloaded with ROS sensitive dye CMH2DCFDA fo llowed by cytokine treatment (IL- lb lng/ml, IFN-g 250ng/ml , TNF-a 4
ng/ml) for 16 hours. ROS production was indicated by increase of CM-H2DCFDA
fl ourescence. Results are typical of 10 to 20 islets per group in two independent
experiments.
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cultured in a medium containing the indicated concentrations of sodium orthovanadate
(vana) and cytokine mixture (cyto IX containing I nglml IL-Ib, 250 nglml interferon-g,
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reduced cytokine mediated islet cell death in MTNOD islets, indicating the
scnscntization to eytokinc toxicity by MI trans gene is relevant to the high activity of
PIPs in MTNOD islets after cytokine treatment. Results came from 2 to 3 independent
experiments with duplicates or triplicates in each experiment.
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VS.

* P<O.OI

for the indicated

MTNOD islets treated with cytokines IX by two-way ANOVA. Vertical bars

indicate the standard error.
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